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INTRODUCTION
INTRODUCTION
Oral route is the most preferred route for the delivery of the drugs till date as it bears
various advantages over the other route of drug administration.1 About 60% of all dosage
forms available are the oral solid dosage form. The lower bioavailability, delayed onset time
and dysphagia in patients turned the manufacturer to the parenterals and liquid orals. But the
liquid orals (syrup, suspension, emulsion etc) have the problem of accurate dosing mainly
and  parenterals  are  painful  drug  delivery2.  Oral  drug  delivery  systems  still  need  some
advancements  to be made because of  their  some drawbacks related to  particular  class  of
patients  which  includes  geriatric  and  pediatric  patients  associated  with  many  medical
conditions  such  as  hand  tremors,  dysphagia in  case  of  geriatric  patients,  underdeveloped
muscular and nervous system in infant and uncooperative patient, the problem of swallowing
is common phenomenon which lead to poor patient compliance.3 The problem of swallowing
tablets was more evident in geriatric and pediatric patients, as well as travelling patients who
may not have ready access to water. Fast-dissolving dosage technologies are important for
patients who have difficulty taking traditional oral dosage forms, as well as those who want
the convenience of any-time dosage when water is not available.4 The oral administrations of
many drugs show first-pass metabolism which results in to lower bioavailability. Limitation
associated with parenteral delivery and poor oral bioavailability needs alternative route for
delivery of such drugs.5
So, fast-dissolving drug-delivery systems came into existence in the late 1970’s as an
alternative to traditional oral solid-dosage forms. These systems consist of the solid dosage
forms that disintegrate and dissolve quickly in the oral cavity without the administration of
water.6
Administration of the drug via the mucosal layer is a novel method that can render
treatment more effective and safe, not only for the topical diseases but for systemic ones.
These unique dosage forms, which can be applied on a wet tissue, are formulated by utilizing
the adhesive properties  of some water soluble polymers.7,8 The distinct  problems that  are
present in the sublingual route like the drug dissolving in the saliva and unpleasant taste, local
anaesthetic effect and odour felt by the patient are absent in the buccal mucoadhesive route.9
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Advantages of buccal drug delivery systems 10 
• Excellent accessibility 
• Results in rapid absorption and onset of action.
• Results in higher bioavailability thus requiring lower doses of drug
• Direct access to the systemic circulation through the internal jugular vein bypasses
drugs from the hepatic first pass metabolism leading to high bioavailability 
• Low enzymatic activity 
• Suitability for drugs or excipients that mildly and reversibly damages or irritates the
mucosa 
• Painless administration 
• Easy drug withdrawal 
• Offers lower risk of overdose
• Facility  to  include  permeation  enhancer/enzyme  inhibitor  or  pH  modifier  in  the
formulation 
• Versatility in designing as multidirectional or unidirectional release systems for local
or systemic actions etc. 
Limitations of buccal drug delivery systems 11
• Drugs, which irritate the oral mucosa, have a bitter or unpleasant taste, odour; cannot
be administered by this route.
• Drugs, which are unstable at buccal pH cannot be administered by this route.
• Only drugs with small dose requirements can be administered.
• Drugs may be swallowed with saliva and thus the advantages of buccal route lost
• Only those drugs, which are absorbed by passive diffusion, can be administered by
this route.
• Eating and drinking may become restricted.
• Swallowing of the formulation by the patient may be possible.
• Over hydration may lead to the formation of slippery surface and structural integrity
of the formulation may get disrupted by the swelling and hydration of the bioadhesive
polymers.
ORAL CAVITY
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The anatomy and physiology of the oral cavity has been well reviewed and will be
considered briefly here. The oral cavity consists of two regions,
 the outer oral vestibule which is bounded by the cheeks, lips, teeth and gingiva (gums)
and
 the oral  cavity proper  which extends from the teeth and gums back to the fauces
(which lead on to the pharynx) with the roof comprising the hard and soft palates.12 
Figure no: 1 Diagram of anatomic locations in the oral cavity
The tongue projects from the floor of the cavity.  The buccal mucosa refers to the
membrane lining the inside of the cheek.12 
Within the oral mucosal cavity, delivery of drugs is classified into three categories, 13
1)  Sublingual  delivery:  This  is  systemic  delivery  of  drugs  through  the  mucosal
membranes lining the floor of the mouth
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2)  Buccal  delivery:  This  is  drug  administration  through  the  mucosal  membranes
lining the cheeks (buccal mucosa) i.e. when a dosage form is placed in the outer vestibule
between the buccal mucosa and gingiva.
3) Local delivery: This is drug delivery into the oral cavity
Drugs  can  be  absorbed  from  the  oral  cavity  through  the  oral  mucosa  either
sublingually or buccaly. In general, rapid absorption from these routes is observed. The oral
cavity  is  lined  by  relatively  thick,  dense  and  multilayered  mucus  membrane  with  high
vasculature. Drugs entering into the membrane can find access to the systemic circulation via
network of  capillaries  and arteries.  The arterial  flow is  supplied  by branches  of  external
carotid artery. The venous back flow goes via capillaries and the venous network is finally
taken up by the jugular vein. The equally developed lymphatic drainage runs more or less
parallel to the venous vascularisation and ends up in the jugular ducts. Thus, the buccal and
sublingual routes can be used to by-pass hepatic first-pass elimination.14
Figure no: 2 Schematic diagram of drug absorption via oral route
Drug absorption  into the mucosa  is  mainly via passive diffusion into the  lipoidal
membrane.  Compounds  with  favourable  o/w  partition  coefficient  are  readily  absorbed
through oral  mucosa.  Compounds  administered by either  the buccal  or  sublingual  routes
include  steroids,  barbiturates,  papain,  trypsin  and  streptokinase,  streptoclornase.  Besides
transcellular diffusion, there is evidence that water soluble molecules with molecular volume
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less  than  80cm3/mol  cross  primarily  through  membrane  pores  and  large  water  soluble
molecules pass paracellularly regardless of polarity, large molecules are poorly absorbed.14
Oral mucosa is a lining tissue that serves to protect the underlying tissues. It consists
of two parts; the underlying epithelium and the connective tissues. The epithelium of the oral
cavity  is  in  principle  similar  to  that  of  the  skin,  with  interesting  differences  regarding
keratinization and the protective and lubricant mucus spread across its surface. The total area
is about 100 cm; the buccal part with about one third of the total surface is lined with an
epithelium of about 0.5 mm thickness and the rest by one of 0.25 mm thickness. The multi-
layered structure of the oral mucosa is formed by cell divisions which occur mainly in the
basal layer. The mucosa of the oral cavity can be divided into three functional zones. 14
Structural Features of Oral Mucosa
Structure:  The  oral  mucosa  is  composed  of  an  outermost layer  of  stratified  squamous
epithelium.  Below  this  lies  a  basement  membrane,  a  lamina  propria  followed  by  the
submucosa as the innermost layer. The epithelium is similar to stratified squamous epithelia
found in the rest of the body in that it has a mitotically active basal cell layer, advancing
through a number of differentiating intermediate layers to the superficial layers, where cells
are shed from the surface of the epithelium.13
The turnover time for the buccal epithelium has been estimated at 5-6 days and this is
probably representative of the oral mucosa as a whole. The oral mucosal thickness varies
depending  on  the  site:  the  buccal  mucosa  measures  at  500-800  µm,  while  the  mucosal
thickness of the hard and soft  palates,  the floor of the mouth, the ventral  tongue and the
gingivae  measure  at  about  100-200  µm.  The  composition  of  the  epithelium  also  varies
depending on the site in the oral cavity. The mucosae of the gingivae and hard palate are
keratinized similar to the epidermis which containe ceramides and acylceramides (neutral
lipids) which have been associated with the barrier function. The mucosa of the soft palate,
the  sublingual  and  the  buccal  regions,  however,  are  not  keratinized  which  are  relatively
impermeable to water and only have small amounts of ceramide.14 They also contain small
amounts of neutral but polar lipids, mainly cholesterol sulfate and glucosyl ceramides. The
nonkeratinized epithelia have been found to be considerably more permeable to water than
keratinized epithelia.15
Figure no: 3 Structure of Oral mucosal membrane
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Permeability: The oral mucosa in general is intermediate between that of the epidermis and
intestinal mucosa in terms of permeability. It is estimated that the permeability of the buccal
mucosa is 4-4000 times greater than that of the skin.16 There are considerable differences in
permeability between different regions of the oral cavity because of the diverse structures and
functions  of the different  oral  mucosa.14 For  the better  absorption of  APIs  in oral  region
permeation enhancer play important role. So if we want to absorb the drug mostly in mouth
as drug released from formulation then there is the need of permeation enhancer.
Composition of Oromucosal Region
Oromucosal Cells: Are made up of proteins and carbohydrates. It is adhesive in nature and
acts as a lubricant, allowing cells to move relative to one another with less friction.19 The
mucus is also believed to play a role in bioadhesion of mucoadhesive drug delivery systems.17
In other part of body mucus is synthesized and secreted by the goblet cells, however in the
oral mucosa, mucus is secreted by the major and minor salivary glands as part of saliva. Up
to 70% of the total mucin found in saliva is contributed by the minor salivary glands.18,19
Characteristics of mucus 31
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The composition of mucus varies widely depending on animal species, anatomical
location and whether the tissue is in a normal or pathological state. Native mucin, in addition
to  mucus,  also  contains  water,  electrolytes,  sloughed  epithelial  cells,  enzymes,  bacteria,
bacterial  by products  and other  debris.  The glycoprotein fraction of the mucus imparts  a
viscous  gel  like  characteristic  to  mucus  due  to  its  water  retention  capacity.  Mucus  is  a
glycoprotein, chemically consisting of a large peptide backbone with pendant oligosaccharide
side  chains  whose  terminal  end  is  either  sialic  or  sulfonic  acid  or  L–fructose.  The
oligosaccharide  chains  are  covalently  linked  to  the  hydroxy  amino  acids,  serine  and
threonine,  along  the  polypeptide  backbone.  About  25%  of  the  polypeptide  backbone  is
without sugars, the so-called ‘naked’ protein region, which is especially prone to enzymatic
cleavage. The remaining 75% of the backbone is heavily glycosylated. The terminal sialic
groups  have  a  pKa  value  of  2.6  so  that  the  mucin  molecule  should  be  viewed  as  a
polyelectrolyte under neutral or acid condition. At physiological pH the mucin network may
carry a significant negative charge because of the presence of sialic acid and sulfate, residues
and this high charge density plays an important role in mucoadhesion.
Role of Mucus32
• Cell-cell adhesion
• Lubrication
• Bioadhesion of mucoadhesive drug delivery systems
Another feature of the oral cavity is the presence of saliva (digestive secretion) produced
by three pairs of salivary glands (parotid, submandibular and sublingual glands). Saliva is
mostly water  with  1% organic and  inorganic materials.  The  digestive  enzyme present  in
saliva is salivary amylase, which breaks down starch molecules to shorter chains of glucose
molecules. Saliva is made from blood plasma and thus contains many of the chemicals that
are found in plasma.  The major  determinant of  the salivary composition is  the flow rate
which in turn depends upon three factors: the time of day, the type of stimulus and the degree
of stimulation.17,19 The salivary pH ranges from 5.5 to 7. The daily salivary volume is between
0.5 to 2 liters and it is this amount of fluid that is available to hydrate oral mucosal dosage
forms.
Role of Saliva 32
• Protective fluid for all tissues of the oral cavity.
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• Continuous mineralization / demineralization of the tooth enamel.
• To hydrate oral mucosal dosage forms. 
A main reason behind the selection of hydrophilic polymeric matrices as vehicles for oral
transmucosal drug delivery systems is this water rich environment of the oral cavity.
DRUG ABSORPTION PATHWAYS 
The drug transport mechanism through the buccal mucosa involves two major routes: 
I) Transcellular route (intracellular)
2) Para cellular route (intercellular)
Figure no: 4 Drug absorption pathways through the buccal mucosa
Studies  with  microscopically  visible  tracers  such  as  small  proteins  and  dextrans
suggest  that  the major  pathway across  stratified epithelium of  large  molecules  is  via  the
intercellular spaces where there is a barrier to penetration as a result of modifications of the
intercellular substance in the superficial layers. It is generally recognized that the lipid matrix
of the extracellular space plays an important role in the barrier function of the paracellular
pathway, especially when the compounds such as peptides are hydrophilic and have a high
molecular weight.20 The absorption potential of the buccal mucosa is influenced by the lipid
solubility and molecular weight of the diffusant. Absorption of some drugs via the buccal
mucosa is found to increase when carrier pH is lowered and decreased by an increase in pH.21
In  general,  for  peptide  drugs,  permeation  across  the  buccal  epithelium is  thought  to  be
through  paracellular  route  by passive  diffusion.  Recently,  it  was  reported  that  the  drugs
having a monocarboxylic acid residue could be delivered into systemic circulation from the
oral mucosa via its carrier.22 The permeability of oral mucosa and the efficacy of penetration
enhancers have been investigated in numerous in vitro and in vivo models. Various kinds of
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diffusion  cells,  including  continuous  flow  perfusion  chambers,  Ussing  chambers,  Franz
diffusion cells and Grass–Sweetana, have been used to determine the permeability of oral
mucosa.23 Cultured epithelial cell lines have also been developed as an in vitro model to study
drug the transport and metabolism at biological barriers as well as to elucidate the possible
mechanisms of action of penetration enhancers.24 Recently, TR146 cell culture model was
suggested  as  a  valuable  in  vitro  model  of  human  buccal  mucosa  for  permeability  and
metabolism  studies  with  enzymatically  labile  drugs,  such  as  leu-enkefalin,  intended  for
buccal drug delivery.
FACTORS AFFECTING DRUG ABSORPTION
Besides  the  biochemical  characteristics  of  the  buccal  and  sublingual  membranes,
which are responsible for the barrier function and permeability, various factors of the drug
molecule influence the extent  of permeation through the membranes.  The lipid solubility,
degree of ionization, pKa of the drug, pH of the drug solution, presence of saliva and the
membrane characteristics, molecular weight and size of the drug, various physicochemical
properties of the formulation, and the presence or absence of permeation enhancers, all affect
the absorption and the permeation of drugs through the oral mucosa.25
Degree of Ionization, pH, and Lipid Solubility
The permeability of unionizable compounds is a function of their lipid solubilities,
determined by their oil–water partition coefficients demonstrated this dependence of water
permeability on the lipid contents of keratinized and non-keratinized epithelia.  The lipids
present however contribute to this effect more in the keratinized epithelia (more total lipid
content, non-polar lipids, ceramides) than in the non-keratinized epithelia where permeability
seems to  be related  to  the  amount  of  glycosylceramides  present.  The  absorption of  drug
through a membrane depends upon its lipophilicity, which in turndepends on its degree of
ionization and partition coefficient. The higher the unionized fraction of a drug, the greater is
its lipid solubility. 25
The degree of ionization in turn depends on the pH of the mucosal membrane and the
pKa of the drug. Beckett and Triggs studied the buccal absorption of basic drugs over a range
of concentration, pH, and the use of different drug combinations (alone and mixtures). The
resultant pH–absorption curves showed that the percentage of drug absorbed increased as the
concentration of drug in the unionized form increased. Also, the shapes of the absorption
curves were a function of the pKa values and the lipidsolubility of their unionized form. A
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study conducted with fentanyl,  a  weak base with a  pKa of  8.2,  further  demonstrated the
relationship between the pH and the absorption across oral  mucosa.  When the pH of the
delivery solution was increased, more of the drug was present in the unionized form, with the
drug being 2.45% unionized at pH 6.6, 9.1% unionized at pH 7.2, and 24% unionized at pH
7.7. The fentanyl solutions with a pH range of 6.6 to 7.7 showed a three- to fivefold increase
in peak plasma concentration, bioavailability, and permeability coefficients. Similar studies
conducted with sublingual administration of opioids such as buprenorphine, methadone, and
fentanyl showed increased absorption with increase in pH, where the drug was predominantly
present in the unionized form. 25
However,  absorption  of  other  opioids  such  as  levorphanol,  hydromorphone,
oxycodone, and heroin under similar conditions did not improve. These drugs, however, were
more hydrophilic as compared to the earlier set of opioids. Thus, pH modifiers can be used to
adjust the pH of the saliva prior to drug administration to increase the absorption of such
drugs through the mucosal  membranes.  However,  the nature of the buccal and sublingual
membrane complicates the above condition since the pH may vary depending on the area of
the membrane and also on the layer  of  the membrane that  is  considered. The pH of  the
mucosal surface may be different from that of buccal and sublingual surfaces throughout the
length of the permeation pathway. Thus, the drug in its unionized form may be well absorbed
from the surface of the membrane, but the pH in the deeper layers of the membrane may
change the ionization and thus the absorption. Also, the extent of ionization of a drug reflects
the partitioning into the membrane,  but  may not reflect  the permeation through the lipid
layers of the mucosa. 25
In  the buccal  absorption study of  propranolol  followed by repeated rinsing of the
mouth with buffer solutions and recovered much of this drug in the rinsing. In addition, the
effect of lipophilicity, pH, and pKa will depend on the transport pathway used by the drug.
Studies conducted with busiprone showed that the unionized form of the drug used the more
lipophilic pathway, the transcellular route, but an increase in the pH increased the ionization
of  the  drug  and  subsequently the  absorption.  It  was  concluded  that  this  transport  of  the
ionized form of the drug was through the more hydrophilic paracellular pathway. Therefore,
at neutral pH the preferred transcellular, but at acidic pH, the ionized species of the drug also
contributed to the absorption across the membrane.
Molecular Size and Weight
The permeability of a molecule through the mucosa is also related to its molecular
size and weight,  especially for hydrophilic substances.  Molecules that  are smaller  in size
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appear to traverse the mucosa rapidly. The smaller hydrophilic molecules are thought to pass
through the membrane pores, and larger molecules pass extracellularly. Increases in molar
volume to greater than 80 mL/mol produced a sharp decrease in permeability.  Due to the
advantages offered by the buccal and the sublingual route, delivery of various proteins and
peptides through this route has been investigated. It is difficult for the peptide molecules with
high molecular weights to make passage through the mucosal membrane. Also, peptides are
usually  hydrophilic  in  nature.  Thus,  they  would  be  traversing  the  membrane  by  the
paracellular route, between cells through the aqueous regions next to the intercellular lipids.
In  addition,  peptides  often  have  charges  associated  with  their  molecules,  and  thus  their
absorption would depend on the amount of charge associated with the peptide,  pH of the
formulation and the membrane, and their isoelectric point. 25
Permeability Coefficient
To compare  the  permeation  of  various  drugs,  a  standard  equation  calculating  the
permeability coefficient can be used. One form of this equation is,
P = % permeated × Vd
        A × t × 100
Where P is the permeability coefficient (cm/s), A is the surface area for permeation,
Vd is the volume of donor compartment, and t is the time. This equation assumes that the
concentration gradient of the drug passing through the membrane remains constant with time,
as long as the percent of drug absorbed is small.
Formulation Factor
The permeation of drugs across mucosal membranes also depends to an extent on the
formulation factors.  These will  determine the amount and rate of drug released from the
formulation,  its  solubility in  saliva,  and thus  the  concentration  of  drug in  the tissues.  In
addition, the formulation can also influence the time the drug remains in contact with the
mucosal membrane. After release from the formulation, the drug dissolves in the surrounding
saliva, and then partitions into the membrane, thus the flux of drug permeation through the
oral  mucosa  will  depend  on  the  concentration  of  the  drug  present  in  the  saliva.  This
concentration can be manipulated by changing the amount of drug in the formulation, its
release rate, and its solubility in the saliva. The first two factors vary in different types of
formulations,  and the last can be influenced by changing the properties of the saliva that
affect the solubility (e.g., pH).
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BIOADHESION
Bioadhesion is an interfacial phenomena in which two materials at least one of which
is  biological  are  held  together  by  means  of  interfacial  forces.  The  attachment  could  be
between an artificial material and biological membrane. In the case of polymer attached to
the mucin layer of mucosal tissue, the term mucoadhesion employed.
Mechanism of Bioadhesion
For bioadhesion to occur, a succession of phenomenon whose role depends on the nature
of the bioadhesive is required.7
 The first stage involves an intimate contact between a bioadhesive and a membrane,
either from a good wetting of the bioadhesive surface or from the swelling of the
bioadhesive.
 In the second stage, after contact is established, penetration of the bioadhesive into the
tissue surface of inter penetration of the chains of the bioadhesive with those of the
mucus, takes place low chemical bonds can then settle.7
On a molecular level mucoadhesion can be explained based on molecular interaction.
The interactions between two molecules are composed of attraction and repulsion. Attractive
interactions  arise  from Vanderwaal  forces,  electrostatic  attraction,  hydrogen  bonding  and
hydrophobic  interaction.  Repulsive  interactions  occur  based  on  electrostatic  and  stearic
repulsion. 7
Theories of Mucoadhesion 27
• The electronic theory proposes transfer of electrons amongst the surfaces resulting in
the formation of an electrical double layer thereby giving rise to attractive forces.
• The wetting theory  postulates that if the contact angle of liquids on the substrate
surface is lower, then there is a greater affinity for the liquid to the substrate surface.
• The adsorption theory proposes the presence of intermolecular forces, viz. hydrogen
bonding and VanderWaal’s forces, for the adhesive interaction amongst the substrate
surfaces.
• The diffusion theory  assumes the diffusion of the polymer chains, present on the
substrate  surfaces,  across  the  adhesive  interface  thereby  forming  a  networked
structure.
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• The mechanical theory explains the diffusion of the liquid adhesives into the micro-
cracks  and  irregularities  present  on  the  substrate  surface  thereby  forming  an
interlocked structure which gives rise to adhesion.
• The cohesive theory proposes that the phenomena of bioadhesion are mainly due to
the intermolecular interactions amongst like-molecules.27
Methods Used To Study Bioadhesion
Several  test methods have been reported for studying bioadhesion. These tests are
necessary not only to screen a large number of candidates to mucoadhesives, but also to study
their mechanisms. These tests are also important during the design and development of a
bioadhesive controlled release system as they ensure compatibility, physical and mechanical
liability, surface analysis and bioadhesive bond strength.8
The test methods can broadly be classified into two major categories.
I). In- vitro/ ex- vivo methods
II). In vivo methods
I): In – vitro / ex - vivo methods: Most in- vitro methods are based on the measurement of
either tensile or shear stress, Bioadhesiveness determined by measurement of stress tends to
be subjective, since there is no standard test method established for bioadhesion.
1. Methods based on measurement of tensile strength:
These  methods  usually  measures  the  force  required  to  break  the  adhesive  bond
between a model membrane and the test polymers. The instruments usually employed are
Modified balance or tensile tester. A typical example is the method employed by Robinson
and his group. In this method, the force required to separate the bioadhesive sample from
freshly excised rabbit stomach tissue was determined using a modified tensiometer.
2. Methods based on measurement of shear strength:
The shear strength measures the force that causes the bioadhesive to slide with respect
to the mucous layer in a direction parallel to their plane of contact. An example is Wilthemy
plate  method reported  by Smart  et  al.  The  method uses  a  glass  plate  suspended  from a
microbalance  which  is  dipped  in  a  temperature  controlled  mucous  sample  and  the  force
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required  to  pull  the  plate  out  of  the  solution  is  determined  under  constant  experimental
conditions.
3. Other in- vitro methods:
A number  of  other  methods  including adhesion  weight  method,  fluorescent  probe
method, flow channel method, mechanical spectroscopic method, falling liquid film method,
colloidal  gold  staining  method,  thumb test,  adhesion  number  and  electrical  conductance
method.
II. In- vivo methods
Various  methods  for  in-vivo  evaluation  of  both  placebo  and  drug  containing
mucoahesive  devices  in  healthy  human  volunteers  have  been  reported  in  the  literature.
Rathbone et al" have discussed several methods to study the rate and extent of drug loss from
human oral mucosa.8
FACTORS AFFECTING MUCOADHESION29
The adhesive bond between a bioadhesive system and mucin gel can be investigated
in term of contribution of the following factors
I. Polymer related factors
• Concentration of active polymer
The polymer concentration was dependable on the physical state (solid/liquid) of the
mucoadhesive drug delivery systems and an increase in the polymer concentration increases
the mucoadhesive strength in solid dosage form while an optimum concentration in liquid
system  was  required  for  best  mucoadhesion.  In  liquid  systems,  beyond  the  threshold
concentration the coiled molecules become separated from the medium limiting availability
of chain for interpenetration thereby dropping adhesive strength significantly.
• Hydrophilicity
Numerous  hydrophilic  functional  groups  like  hydroxyl  and  carboxyl,  of  the
bioadhesive  polymers;  aids  swelling  in  aqueous  media  leading  to  maximal  exposure  of
potential anchor sites and subsequent hydrogen bonding with the substrate.
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• Spatial conformation
Along with  molecular  weight  or  chain  length;  spatial  or  helical  conformation  the
polymer chain, that may shield many adhesively active groups responsible for adhesion in
comparison to that with linear conformation; plays important role in the mucoadhesion.
• Molecular weight
Low-molecular-weight of polymer favours interpenetration of molecules while higher
molecular weight favours entanglements. Type of the mucoadhesive polymer and the tissue
determines  the  optimum  molecular  weight  for  maximum  mucoadhesion.  The
bioadhesive/mucoadhesive  force  increases  with  an  increase  in  the  molecular  weight  of
polymer up to 100,000 and beyond this level there was not much effect.
• Flexibility of polymer chains associated with cross-linking and swelling
Flexibility was important for interpenetration and entanglement. As the cross linking
density of  water-soluble  polymer  increases;  the mobility of  the  individual  polymer chain
decreases; and the effective length of the chain that can penetrate into mucous layer decreases
even further  consequently mucoadhesive strength decreases.  Too great  degree of swelling
results in slippy mucilage and can be easily removed from the substrate. Polymers grafting
onto the preformed network; and the inclusion of adhesion promoters in the formulation (free
polymer); enhances mucoadhesion of crosslinked polymers.
II. Environment related factors
 pH of polymer-substrate interface
The  hydrogen  ion  concentration  can  influence  charge  on  the  surface  of  mucous,
associated with dissociation of functional groups on the carbohydrate moiety and amino acids
of  polypeptide  backbone;  as  well  as  certain  ionisable  mucoadhesive  polymers.  Studies
depicted that the pH of the medium was important for the degree of hydration of cross linked
polyacrylic acid that consistently increases from pH 4 through pH 7 and then decrease as
alkalinity and ionic strength increases. Polycarbophil shows maximum adhesive strength at
pH 3 that gradually decreases with an increase in pH up to 5 and above pH 5 it does not show
any mucoadhesive property.  Protonated carboxyl  groups,  rather  than the ionised carboxyl
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groups,  react  with mucin molecules,  apparently by the concurrent formation of numerous
hydrogen bonds.
 Initial contact time
Initial contact time between the mucoadhesive and the mucus layer determines the
extent of swelling and the interpenetration of polymer chains. An increase in initial contact
time increases mucoadhesive strength.
 Applied strength
The pressure initially applied on the solid bioadhesive system to apply on mucosal
tissue can affect the depth of interpenetration, and the adhesive strength increases with an
increase in the applied strength or with the density up to an optimum value.
 Secretion of the model substrate surface
Studies on the variability of biological substrate should be confirmed by examining
properties like permeability, electro physiology, or histology etc., before and after performing
the in vitro tests using tissues for the better in vitro/in vivo correlation.
 Swelling
Bioadhesion decreases with too great swelling that depends on the presence of water
and on the polymer concentration. In order to achieve sufficient bioadhesion of the system,
too early swelling must not occur.
III. Physiological variables
o Mucin turnover
The natural turnover of mucin molecules from the mucous layer not only limits the
residence time of the mucoadhesive on the mucous layer but also released out soluble mucin
molecules, insubstantial amount, interacts with mucoadhesives before they have a chance to
interact with mucous layer. An increase in mucin turnover decrease mucoadhesion.
o Disease state
In  diseased conditions;  like common colds,  gastric ulcers,  ulcerative colitis,  cystic
fibrosis, bacterial and fungal infections of the female reproductive tract, and inflammatory
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conditions  of  the  eye;  the  physicochemical  properties  of  the  mucous  changes.  The
mucoadhesive property needs to be evaluated, if mucoadhesives are intended to be used in
the diseased state.
BUCCAL ADHESIVE DOSAGE FORMS 
Several buccal adhesive delivery devices were developed at the laboratory scale by
many researchers either for local or systemic actions and can be broadly classified in to solid
buccal adhesive dosage forms, semi-solid buccal adhesive dosage forms and liquid buccal
adhesive dosage forms. Some commercially available buccal adhesive formulations are listed
in table no.1.
 Solid buccal adhesive formulations 
Solid buccal adhesive formulations achieve bioadhesion via dehydration of the local
mucosal surface. They include tablets, micro particles, wafers, lozenges etc.
Tablets 
Buccal adhesive tablets that are placed directly onto the mucosal surface for local or
systemic drug delivery have been demonstrated to be excellent  bioadhesive formulations.
Two types of tablets i.e. monolithic and double-layered matrix tablets have been investigated
for buccal delivery of drugs. Monolithic tablets consist of a mixture that contains drug and
swelling bioadhesive/sustained release polymer. These tablets exhibit a bidirectional release.
They  can  be  coated  on  the  outer  or  on  all  sides  but  one  face  with  water  impermeable
hydrophobic substances to allow a unidirectional drug release for systemic delivery. 
Double layered tablets comprise an inner layer based on a bioadhesive polymer and
an outer non-bioadhesive layer containing the drug for a bi-directional release but mainly a
local action. In the case of systemic action, the drug is loaded into the inner bioadhesive layer
whereas the outer layer is inert and acts as a protective layer. Alternatively, the drug is loaded
into  a  controlled  release  layer  and  diffuses  towards  the  absorbing  mucosa  through  the
bioadhesive layer, whereas a water impermeable layer assures the mono-directional release.
Microparticles 
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Bioadhesive microparticles offer  the same advantages  as  tablets  but  their  physical
properties  enable  them  to  make  intimate  contact  with  a  lager  mucosal  surface  area.  In
addition, they can also be delivered to less accessible sites including the GI tract and upper
nasal cavity.19
Wafers 
A conceptually  novel  periodontal  drug  delivery  system  that  is  intended  for  the
treatment of microbial infections associated with peridontitis was described elsewhere. . The
delivery system is a  composite  wafer  with surface  layers  possessing adhesive properties,
while  the  bulk  layer  consistsof  antimicrobial  agents,  biodegradable  polymers  and  matrix
polymers.19
Lozenges 
Bioadhesive lozenges may be used for the delivery of drugs that act topically within
the  mouth  including  antimicrobials,  corticosteroids,  local  anaesthetics,  antibiotics  and
antifungals.19
 Semi-solid dosage forms 
Gels 
Gel forming bioadhesive polymers include crosslinked polyacrylic acid that has been
used  to  adhere  to  mucosal  surfaces  for  extended  periods  of  time and  provide  controlled
release of drugs. 
Patches / films. 
Flexible films may be used to deliver drugs directly to a mucosal membrane. They
also offer advantages over creams and ointments in that they provide a measured dose of drug
to the site. Buccal adhesive films are already in use commercially.19 
Patch systems are the formulations that have received the greatest attention for buccal
delivery of drugs. They present a greater patient compliance compared with tablets owing to
their  physical  flexibility  that  causes  only  minor  discomfort  to  the  patient.  Patches  are
laminated and generally consist of an impermeable backing layer and a drug-containing layer
that  has  mucoadhesive  properties  and  from  which  the  drug  is  released  in  a  controlled
manner.19
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 Liquid dosage forms 
Viscous liquids may be used to coat buccal surface either as protectants or as drug
vehicles  for  delivery to  the  mucosal  surface.  A novel  liquid  aerosol  formulation (Oralin,
Generex  Biotechnology)  has  been  recently developed,  and  it  is  now in clinical  phase  II
trials.This system allows precise insulin dose delivery via a metered dose inhaler in the form
of fine aerosolized droplets directed into the mouth.19
Table no: 1 Commercially available buccal adhesive formulations.
Brand Name Bioadhesive Polymer Company Dosage forms 
Buccastem PVP, Xanthum gum, 
Locust bean gum 
Rickitt Benckiser Tablet 
Suscard HPMC Forest Tablet 
Gaviscon Liquid Sodium alginate Rickitt Benckiser Oral liquid 
Orabase Pectin,Gelatin Orabase Pectin,gelatin 
Corcodyl gel HPMC Glaxosmithkline Oromucosal Gel 
Corlan pellets Acacia Celltech Oromucosal Pellets 
Fentanyl Oralet tm                     Lexicomp Lozenge
Miconaczole Lauriad                    Bioalliance Tablet
Emezine TM BDSI’s 
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LITERATURE REVIEW
Research articles for Promethazine HCl
1. Roger Dale Graben (2006) developed a simple, inexpensive method of manufacturing
ODTs.  Promethazine HCL was  chosen  as  a  model  drug.  Taste-masking studies  were
conducted  by  directly  mixing  Promethazine  with  a  number  of  substances.  A  1:1
Magnesium Stearate:  Promethazine mixture  V-blended  for  one  hour was  effective in
masking the bitter taste of this drug. Rapid disintegration was achieved with Mannitol
and Dextrates even with large amount of Magnesium Stearate. Tablets were produced
with various combinations of disintegrants with various mechanisms of action. Flavor
and  sweetener  trials  were  conducted.  A combination  of  Promethazine,  Magnesium
Stearate, Dextrates, and disintegrants was found to yield robust tablets (Friability < 1.0%
with 0 broken at 25 rpm, for 4 minutes) with rapid disintegration (in vitro < 21 seconds,
in vivo < one minute). Although the bitter taste was masked, the unpleasant anesthetic
effect was not completely eliminated. The addition of 3.0% Menthol with sublimation
post-tableting resulted in a visibly more porous tablet with shorter in vitro and in vivo
disintegration  times.  These  tablets  yielded  a  pleasant  taste  without  numbing.  These
tablets  met  compendial  Dissolution  and  Content  Uniformity  requirements  for
conventional  Promethazine  tablets.  These  trials  indicate  an  acceptable  ODT can  be
produced  using  conventional  excipients  and  simple  blending  followed  by  direct
compression. In the case of Promethazine, the addition of Menthol followed by post-
tableting sublimation was required to overcome the unpleasant numbing effect. While the
sublimation of Menthol is an additional step, it only required a common laboratory oven
and 48 hours.40 
2. Sachin et al (2009) prepared fast dissolving tablets of Promethazine HCL Taste masked
granules  were  prepared  using  gastro  erodible  aminoalkyl  methacrylate  copolymers
(Eudragit E-100) by extrusion method. Fast dissolving tablets were prepared using taste-
masked  granules  and  a  mixture  of  excipients  containing  optimized  level  of
microcrystalline  cellulose  (Avicel  PH-101)  and  starch.  The  effect  of  various  super
disintegrants  like  crospovidone,  Sodium Starch  Glycolate  (Primogel),  Croscarmellose
sodium  (Ac-Di-Sol)  was  also  studied.  The  tablets  were  punched  using  rotary  press
tableting machine. The complexation of Promethazine HCl with Eudragit E100 helps to
mask its bitter taste as well as it improves the dissolution profile.39
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3. Ganesh kumar Gudas et al (2010) prepared fast dissolving tablets of Promethazine.HCl
using five superdisintegrants viz; sodium starch glycolate, crospovidone, croscarmellose,
L-HPC and  pregelatinised  starch.  The precompression blend  was  tested  for  angle  of
repose,  bulk  density,  tapped  density,  compressibility  index  and  Hausner’s  ratio.  The
tablets were evaluated for weight variation, hardness, friability,  disintegration time (1
min), dissolution rate, content uniformity, and were found to be within standard limit. It
was concluded that the fast dissolving tablets with proper hardness, rapidly disintegrating
with enhanced dissolution can be made using selected superdisintegrants.  Among the
different  formulations  of  Promethazine.HCl  was  prepared  and  studied  and  the
formulation  containing  crospovidone,  mannitol  and  microcrystalline  cellulose
combination was found to be the fast  dissolving formulation. In the present study an
attempt has been made to prepare fast dissolving tablets of Promethazine.HCl, by using
different superdisintegrants with enhanced disintegration and dissolution rate.36
4. Sandeep (2011) made formulations of rapid dissolving tablets of Promethazine HCl by
direct compression method with the aid of superdisintegrant addition. Nine formulations
were developed using three different superdisintegrants in varying concentrations. All the
formulated tablets were subjected for pre and post-compression evaluation parameters. A
comparison  of  in  vitro  drug  release  of  optimized  formulation  was  compared  with
marketed product (Phenargan). Among the nine formulations, the formulation containing
5% crospovidone showed highest  drug release of  98.43% than other  formulations.  A
comparison of  in vitro  drug release was made with marketed product of Promethazine
HCl (Phenargan) which shows 93% drug release in 1 hour. That formulated tablets of
Promethazine HCl containing crospovidone are better  and effective than conventional
tablets to meet patient compliance and give fast relief from vomiting and emesis. 34
5. Rao  et  al  (2012) developed  mucoadhesive  patches  for  transbuccal  delivery  of
Promethazine hydrochloride to overcome the extensive first-pass metabolism by solvent
casting technique with Hydroxy ethyl cellulose and Hydroxylpropyl methyl cellulose as
mucoadhesive polymers  and propylene glycol as the plasticizer.  They evaluated their
physicochemical characteristics, in vitro drug release, moisture absorption, surface pH,
mechanical  properties,  in vitro bioadhesion, in vivo residence time, and ex vivo drug
permeation  through  porcine  buccal  membranes  and  stability  studies.  Ex  vivo  drug
permeation through porcine buccal membrane was 83.7% in 6 hours with flux 0.19 mg
h–1cm–2. The optimized formulation showed maximum drug release (98%) in 6 hours in
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the  Higuchi  model  release  profile.  In  vivo  mucoadhesive  behaviour  was  studied  in
healthy human volunteers and subjective parameters were evaluated. The stability studies
showed no significant changes in drug content, in vitro release and ex vivo permeation
after 6 months.33
Research works on buccal patches
6. Chandra Sekhar et al (2008) developed and evaluated mucoadhesive buccal patches of
prochlorperazine (PCPZ).  Permeation of  PCPZ was calculated  in  vitro using porcine
buccal  membrane.  Buccal  formulations  were  developed  by solvent  casting  technique
using hydroxyl propylmethyl cellulose (HPMC) as mucoadhesive polymer. The patches
were evaluated for in vitro release, moisture absorption and mechanical properties. The
optimized formulation, based on in vitro release and moisture absorption studies, was
subjected for bioadhesion studies using porcine buccal membrane. In vitro flux of PCPZ
was  calculated  to  be  2.14±0.01µg.  H-1.cm-2  and  buccal  absorption  was  also
demonstrated  in-vivo in human volunteers.  In vitro drug release and moisture absorbed
was governed by HPMC content. Increasing concentration of HPMC delayed the drug
release. All the formulations followed Zero order release kinetics whereas the release
pattern  was  non-Fickian.  The  mechanical  properties,  tensile  strength  (10.28±2.27  kg
mm-2 for  formulation  P3) and  elongation  at  break  reveal  that  the  formulation to  be
strong but not brittle. The peak detachment force and work of adhesion for formulation
P3 were 0.68±0.15 N and 0.14±0.08 mJ, respectively. The results indicate that suitable
bioadhesive buccal patches of PCPZ with desired permeability and suitable mechanical
properties could be prepared.43
7. Alagusundaram  et  al  (2009) prepared  mucoadhesive  buccal  films  of  ranitidine  by
solvent casting technique using polymers like hydroxy propyl methyl cellulose-15 cps
and  poly  vinyl  pyrrolidone.  The  formulated  films  were  evaluated  for  their
physiochemical parameters like surface pH, percentage moisture absorption, percentage
moisture loss, swelling percentage, water vapour transmission rate, thickness, weight of
the films, folding endurance and drug content.  In vitro release studies were performed
with  pH 6.8  phosphate  buffer  solution.  Good  results  were  obtained  both  in  physico
chemical characteristics and in vitro studies. The films exhibited controlled release more
than 10 h. The in vitro release data were fit to different equations and kinetic models to
explain release profiles. The kinetic models used were zero order, Higuchi’s and Peppa’s.
The best mucoadhesive performance and matrix controlled release was exhibited by the
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formulation  R5  (2  %  HPMC  and  1  %  PVP).  The  correlation  coefficient  value  (r)
indicates the kinetic of drug release was zero order. The formulation was found to be
right and suitable candidate for the formulation of ranitidine buccal film for therapeutic
use.46
8. Biswajit  Basu  et  al  (2010) prepared  buccal  mucoadhesive  patches  for  oral  mucosal
delivery of Pimozide an antipsychotic agent, which is having rapid absorption and less
bioavailability due to firstpass metabolism. Different combinations of polymers HPMC
(47cPs, 15cPs), PVA, Carbopl-934 and PVP were used with glycerine as plasticizer. In
vitro release studies of the patches showed 55.32% to 97.49% drug release in 60min. and
in vivo absorption studies for all patches ranged from 47.96% to 83.42% in 60min. in
human volunteers.  Also in vivo studies in rabbits showed 85.97% of drug absorption
from HPMC 15cPs patch in 60min. Good correlation among in vitro release and in vivo
absorption of pimozide was observed. 37
9. Ananta  Choudhury  et  al  (2010)  designed  a  sustained  release  film  formulation  of
Ciprofloxacin hydrochloride for the treatment of periodontal diseases and investigated
different  experimental  parameters  to  conclude  in  details  about  its  different
characteristics.  Films  were  formulated  using  different  concentration  HPMC  and
polyvinyl  alcohol.  The  prepared  films  were  subjected  to  different  evaluation  like
determination  of  weight,  thickness,  surface  pH,  folding  endurance,  swelling  index,
mucoadhesion time, mucoadhesion strength, drug content, in vitro drug release study, ex-
vivo release study and release kinetic behavior.  From the results of evaluation it  was
concluded  that  all  the  prepared  films  having  desire  flexibility  and  mucoadhesive
properties,  along  with  that  they  shows  good  in-vitro  and  ex-vivo  drug  release
performance. Drug release from the films follows desire sustained release phenomenon
as needed in buccoadhesive drug delivery. 38
10. Marina et al (2010) prepared mucoadhesive buccal films of losartan potassium were
prepared using hydroxypropyl methyl cellulose (HPMC) and retardant polymers ethyl
cellulose (EC) or eudragit RS 100. Thermal analysis by DSC of formulations shows no
interaction between drug and polymers. Ex vivo permeation studies of losartan potassium
solution through porcine buccal mucosa showed 90.2 % absorption at the end of 2 hours.
The films  were  subjected  to  physical  investigations  such as  uniformity of  thickness,
weight, drug content, folding endurance, tensile strength, elongation at break, surface pH
and mucoadhesive strength.  Films were flexible and those formulated from EC were
smooth  whereas  those  prepared  from  Eudragit  were  slightly  rough  in  texture.  The
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mucoadhesive force, swelling index, tensile strength and percentage elongation at break
was higher for those formulations containing higher percentage of HPMC. In vitro drug
release studies reveal that all films exhibited sustained release in the range of 90.10 to
97.40  % for  a  period  of  6  hours.  The data  was  subjected  to  kinetic  analysis  which
indicated  non  fickian  diffusion  for  all  formulations  except  E2.  Ex  vivo  permeation
studies through porcine buccal mucosa indicate that films containing higher percentage
of the mucoadhesive polymer HPMC showed slower permeation of the drug for  6-7
hours.48
11. Anuj et al (2011) prepared Carvedilol buccal mucoadhesive patches using HPMC K15M
and Carbopol 940. The patches were evaluated for their thickness, folding endurance,
weight and content uniformity, swelling behaviour, mucoadhesive strength and surface
pH. In vitro drug release int the range of 77.05 to 97.20% in 8hrs. Data of invitro release
from patches were fed into kinetic models (Higuchi and Korsmeyer-Peppas models) to
explain release profiles. The optimized formulation showed zero order release.50
12. Raghavendra Rao et al (2011) have prepared buccal films of Zolmitriptan in order to
improve  the  bioavailability  and  efficacy  using  different  mucoadhesive  polymers  by
Solvent Casting Technique. Buccal films were characterized for number of parameters
like  physical  appearance  and  surface  texture,  weight  uniformity,  thickness,  folding
endurance, swelling index, surface pH, drug content uniformity, in-vitro residence time,
tensile strength, drug excipients interaction study, and in-vitro drug release study. All the
prepared films were smooth surface and elegant texture and weighed in between 20.66 to
26.66 mg. The thickness of the films was in the range of 0.220 to 0.306 mm. Folding
endurance was in the range of 265 to 295. Swelling index was in the range of 29.93 to
40.15 %. Surface pH was in the range of 6.50 to 6.83 pH. Drug content uniformity study
showed uniform dispersion of the drug throughout the formulation in the range of 95.66
to 98.54 %. The in-vitro residence time for all the films is in between 4.36 to 8.23 hrs.
The tensile strength of films is in the range of 6.233 to 4.533 Kg/cm2.  FT-IR studies
revealed that, there was no incompatibility of the drug with the excipients used. In-vitro
drug release studies in the range of 71.22 to 96.55 in 10 hrs. Formulations like ZBF1 and
ZBF3 shows highest drug release at 10th hrs 96.55%, 83.60% respectively. Release of
Zolmitriptan  from  all  films  followed  zero  order  and  mechanism  was  diffusion  rate
limited. 35 
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13. Muaadh  Mohamed  et  al  (2011)  developed  and  characterized  mucoadhesive  drug
delivery systems for diltiazem hydrochloride in the form of buccal films for improving
bioavailability.  Sodium carboxymethyl cellulose (SCMC) and hydroxypropyl cellulose
(HPC) were used either alone or in combination for film fabrication. Prepared films were
evaluated for various physicochemical characteristics such as weight variation, thickness,
drug content uniformity, folding endurance, surface pH, and in vitro drug release. The in
vitro  mucoadhesive  strength  and  permeation  studies  were  performed  using  chicken
pouch mucosa.  Further,  in vivo testing of mucoadhesion time and acceptability were
performed in human subjects.  Results indicated that  drug release,  swelling index and
mucoadhesion performance were found to depend upon polymer type and proportion.
The  majority  of  the  developed  formulations  presented  suitable  adhesion  and  the
mechanism of drug release was found to be non-Fickian diffusion. Good correlation was
observed between in vitro drug release and in vitro drug permeation with correlation
coefficient  ranged  between  of  0.945  to  0.980.  In  addition,  from  healthy  human
volunteers, bioadhesive behavior was found to be satisfactory. Drug bioavailability of a
selected diltiazem hydrochloride adhesive buccal film, F26 (1% HPC and 2%SCMC)
was determent  and compared with that  of  a  commercial  sustained release oral  tablet
(Altiazem® RS) as a reference formulation. The obtained Cmax and AUC0-∞  values
were higher for buccal administration than oral administration and the difference was
statistically  significant  (p  <0.05).  The percentage  relative bioavailability  of  diltiazem
hydrochloride from the selected buccal mucoadhesive film in rabbits was found to be
165.2%.41
14. Mahalaxmi  et  al  (2011)  developed  a  mucoadhesive  buccal  film  of  Betamethasone
sodium phosphate by solvent casting method using HPMC E5 LV and carbopol 940P as
polymer, PEG 1000 as plasticizer. All the formulations were examined for film thickness,
weight variation, drug content, percentage moisture loss, percentage moisture absorption,
surface pH, folding endurance, tensile strength, in vitro and in vivo residence time and in
vitro release. In vitro and in vivo residence time of all formulations showed above 30
min. Formulation F3 showed optimum tensile strength 7.72±0.41kg/mm2, 88.59 ± 2.74%
in vitro drug release at the end of 30 min and showed good stability.49
15. Harshad  et  al  (2011) prepared  Lidocaine  HCl  patches  were  prepared  using  32  full
factorial design by solvent casting technique. Experimental work was carried out using
film-forming  and  mucoadhesive  polymer  such  as  HPMC  E-15  and
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carboxymethylcellulose sodium (NaCMC) alone and successively in combination with
mucoadhesive polymers. All the formulations carried drug and Propylene glycol (PG) in
water  as  a  solvent.  Drug-excipient  interaction  study  was  carried  out  using  FTIR
technique. Films were evaluated for their weight, thickness, surface pH, swelling index,
in vitro residence time, folding endurance, in vitro release, in- vitro permeation and drug
content uniformity. The optimized batch showed good mucoadhesion and gave more than
80% drug release within 3hrs and gave maximum release 97%. The release kinetic best
fitted to Higuchi model. From Higuchi model we can say the mechanism of drug release
is diffusion controlled.42
16. Rani et al (2012) designed a new formulation Mucoadhesive buccal film of Hydralazine
hydrochloride  using  different  polymers  like  Hydroxy propyl  methyl  cellulose  K4M,
Carbopol 934p with different concentrations and plasticizer (poly ethylene glycol4000)
by solvent casting method and it is used for treatment of hypertension in the oral cavity
and for good retention property on the site. The formulated buccal film of Hydralazine
Hydrochloride  evaluated  for  weight  and  thickness  uniformity,  folding  endurance,
swelling  index,  content  uniformity,  Invitro drug  release  using  Franz-  diffusion  cell,
residence time and mucoadhesive strength. The films containing high concentrations of
Hydroxy propyl methyl celluloseK4M shows good swelling and mechanical properties,
and  invitro drug  release.  Formulation  containing  similar  ratio  (1:1)  of  HPMC  and
carbopol shows high drug content uniformity and invitro drug release. And formulation
containing  higher  concentrations  of  carbopol  shows  positive  effect  on  mucoadhesive
strength and residence time.47
17. Mamatha et  al  (2012) prepared Mucoadhesive buccal  patches  of  Aceclofenac using
different  polymers  like  hydroxypropyl  methylcellulose,  Carbopol  934-P,  polyvinyl
alcohol,  polyvinyl  pyrrolidone  K-30,  Eudragit  L-100  in  various  proportion  and
combinations by solvent casting method. The prepared patches were smooth, elegant in
appearance, uniform in thickness, mass and drug content. All the formulation showed
folding endurance of <100. A 32 full factorial design was employed to study the effect of
variable polymers like Carbopol 934-P and PVP K-30, hydroxypropyl methylcellulose,
which significantly influenced characteristics like swelling index and ex vivo residence
time of Aceclofenac buccal patches.  In vitro  drug release and  in vitro drug permeation
study showed that, from the formulation F10, the drug is released and permeated fastly.
All the formulations were best fitted to Higuchi model. The stability study of selected
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patches was done in natural human saliva and it was found that all the patches were
stable in human saliva.44
18. Vandana  et  al  (2013) developed  a  controlled  release  drug  delivery  device  of  anti-
diabetic drug i.e.,  Glipizide to maintain its bioavailability over an extended period of
time and to circumvent the hepatic first pass effect. To achieve this object, Drugcoat and
HPMC  were  used  as  a  polymer  for  the  preparation  primary  and  secondary  layer
respectively, of controlled release bilayerd buccoadhesive patches of drug. The prepared
patches were evaluated for various  in vitro  and  in vivo  studies. From the study it was
concluded that the developed bilayered buccoadhesive delivery system bears potential to
deliver the drug in a controlled manner over an extended period of time.45
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Scope of Work
Motion sickness or kinetosis, also known as travel sickness, is a condition in which
there exists a disagreement between visually perceived movement and the vestibular system's
sense  of  movement.51 Nausea,  dizziness,  fatigue  and  headache  are  the  most  common
symptoms of motion sickness.52 About 30% of people are susceptible to motion sickness.53 A
wide  range  of  drugs  have  proven  to  be  effective  against  nausea  and  vomiting  like
antihistamines, anticholinergics, dopamine receptor antagonists, 5–HT3 receptor antagonists
and gastro prokinetic agent.
Promethazine hydrochloride is the most suitable drug of choice to be used to prevent
nausea  associated  with motion  sickness.52 It  is  first  generation  anti-histamine  of
phenothiazines  family.55 Promethazine  hydrochloride  competes  with  free  histamine  for
binding  at  H1-receptor  sites  in  the  GI  tract,  uterus,  large  blood  vessels,  and  bronchial
muscle.56 The relief of nausea appears to be related to central anti-cholinergic actions and
may implicate activity on the medullary chemoreceptor trigger zone.54 It  acts mainly as a
strong  antagonist  of  the  H1 receptor  (antihistamine)  and  a  moderate  mACh  receptor
antagonist,  hence  it  blocks  the  action  of  acetylcholine  on  the  receptors  (anticholinergic
effect),  and  this  explains  its  benefit  in  reducing  the  nausea  experienced  during  motion
sickness.55,57 
Promethazine HCL is highly soluble & highly permeable drug (BCS Class I). It  is
completely absorbed following oral administration.54 Peak plasma concentrations have been
seen after 2 to 3 hours after a dose by these routes. But its systemic bioavailability after oral
doses is very low (about 25%) which is mainly due to extensive first-pass metabolism in the
liver.57
Oral mucosal drug delivery is an alternative method of systemic drug delivery that
offers several advantages over both injectables and enterable method.47 It  is found that the
absorption of the drug from oral mucosa is via passive diffusion into the lipoidal membrane.14
Buccal absorption is more rapid in action. This area is highly perfused and peak blood levels
of most drugs can be achieved within 10-15 min by sublingual administration.  Also it  is
possible  to  bypass  the  first  pass  effect  and  thus  bioavailability  can  be  improved
significantly.47 
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Rapid onset  of  action is  of  prime importance in  patients with  nausea and motion
sickness.55
Promethazine HCl is commercially available as  conventional dosage forms such as
tablets (12.5, 25, and 50 mg), syrup (6.25 mg/5 ml), suppositories (12.5, 25, and 50 mg), and
injections (25 mg/ml and 50 mg/ml).57
The present study was undertaken to prepare and to evaluate the buccal patches of
Promethazine Hydrochloride for the rapid and effective treatment of the motion sickness.
Objective of the Work
The main objectives of the present work are
• To prepare the buccal patches of the Promethazine hydrochloride with the use of film
forming polymer hydroxyl propyl methyl cellulose.
• To evaluate the formulated patches for various characteristics and properties.
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PLAN OF THE WORK
Plan of work is outlined below:-
I) Preformulation studies
a. Construction  of  standard  curve  of  Promethazine  hydrochloride  by  UV
spectrophotometry
b. Drug excipients compatibility study.
II) Fabrication of buccal patches
a.  Preparation and evaluation of drug loaded patches
i) Preparation of drug loaded HPMC patches.
ii) Evaluation of patches for
a. Thickness
b. Folding endurance
c. Weight variation
d. Drug Content
e. Surface pH
f. Swelling index
g. Tensile strength
h. Mucoadhesive strength
i. In vitro drug release 
i.    Ex vivo drug permeation
k.   In vivo compatibility.
ULTRA COLLEGE OF PHARMACY, MADURAI 30
MATERIALS AND METHODS
MATERIALS AND METHODS 
LIST OF MATERIALS USED
                                         Table No: 2 List of Materials
S.No Chemicals and reagents Supplier
1 Promethazine hydrochoride  Gift sample from Watson Pharma, Goa
2 Hydroxy propyl methyl cellulose K4M Orchid Healthcare, Chennai
3 Hydroxy propyl methyl cellulose 15cps S.D.Fine chem ltd. Mumbai
4 Glycerin S.D.Fine chem ltd. Mumbai
5 P E G 400 S.D.Fine chem ltd. Mumbai
6 Propylene glycol S.D.Fine chem ltd. Mumbai
7 Potassium dihydrogen ortho-phosphate Qualigens FineChem. Mumbai
8 Sodium hydroxide Merk limited. Mumbai
9 Fresh Buccal mucosa of Goat From local Slaughter House
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LIST OF INSTRUMENT USED                                 
                        Table No: 3 List of Instrument Used
Sl.no. Name of instrument/ Equipments Manufacture
1 Electronic balance (BL-2200H) Shimadzu corporation
2 Dissolution apparatus USP VI Lab India Disso-8000
3 UV-Visible double beam 
spectrophotometer Systronic 118
4 Bath Ultrasonicator Ultrasonic cleaner C80-4, Confident equipments
5 FTIR Perkin Elmer, KMCP Madurai
6 Desiccator Qualigens Fine Chem. Mumbai
7 Dial gauge Baker Precision measuring instruments
8 Magnetic stirrer (2MLH) Remi equipment Pvt Ltd. Mumbai
9 Microwave oven Magic cook, Whirlpool
10 Micropipette variable Tarson Pvt.Ltd
11 Vacuum oven Shavani Scientific Pvt. Mumbai
12 TA.XT plus Texture analyzer Stable Microsystems, U.K
13 Diffusion cell Modern Scientific, Madurai
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DRUG PROFILE
PROMETHAZINE HYDROCHLORIDE57-59
Chemical structure   :
                                                  
Molecular Formula   : C17H20N2S  HCl 
Molecular Weight    : 320.9g/ml
Chemical Name    : (RS)-dimethyl(2- phenothiazin-10-ylpropyl) amine 
  hydrochloride. 
Solubility          : very soluble in water, freely soluble in alcohol, chloroform,
               insoluble in ether
Melting point : 220-222°C
pKa value : 9.1
pH : 5.8
Log P :  4.7
Dose : 10mg to 25mg and maximum dose per day is 25mg 
Storage : store in a cool dry place, away from direct heat and light.
Beer’s range : 1-10µg/ml
Properties : Promethazine hydrochloride appears as a white to faint yellow
crystalline powder that is practically odourless. Slow oxidation may occur upon prolonged
exposure to air usually causing blue discolouration.
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Mechanism of Action    :  Promethazine  hydrochloride  is  a  phenothiazine,  is  an  H1
antagonist  with  anticholinergic,  sedative,  antiemetic  effects  and  some  local  anaesthetic
properties. Promethazine competes with free histamine for binding at H1-receptor sites in the
GI tract, uterus, large blood vessels, and bronchial muscle. The relief of nausea appears to be
related  to  central  anti-cholinergic  actions  and  may  implicate  activity  on  the  medullary
chemoreceptor trigger zone. 
Pharmacokinetics     :  Following oral  absorption, Promethazine HCl is completely
absorbed, with absolute bioavailability of 25% due to first pass metabolism. The apparent
mean elimination half-life of Promethazine HCl generally ranges from 16 to 20 hours. It is
metabolized by the cytochrome P450 2D6 (CYP2D6). Following oral dosing of promethazine
an  average  of  60%  and  20%  of  total  metabolites  are  recovered  in  the  urine  and  feces,
respectively. Promethazine HCl was 30% bound to plasma proteins, primarily with albumin.
It is  extensively  distributed  throughout  the  body  with  a  mean  steady  state  volume  of
distribution of 2.4 L/kg.
Contraindications         : Promethazine  HCl  is  contraindicated  in  comatose  states,
in patients  who have received large amounts of central-nervous-system depressants (alcohol,
sedatives   hypnotics,  including  barbiturates,  general  anaesthetics,  narcotics,  narcotic
analgesics,  tranquilizers, etc.), and in patients who have demonstrated an idiosyncrasy or
hypersensitivity  to promethazine. Phenergan tablets and suppositories are contraindicated in
comatose  states,  and  in  individuals  known  to  be  hypersensitive  or  to  have  had  an
idiosyncratic reaction to promethazine or to other phenothiazines.
Adverse effects  :  Adverse  effects  include  restlessness,  drowsiness  and
diarrhoea, hypotension.  Hypertension, dizziness, headache and depression may occur and
there are isolated reports of blood disorders, hypersensitivity reactions (rash, bronchospasm)
and neuroleptic malignant syndrome. Promethazine stimulates prolactin secretion and may
cause  galactorrhoea  or  related  disorders.  Transient  increase  in  plasma  aldosterone
concentrations has been reported.
Drug interactions : In-vitro studies of cytochrome P450 isoenzymes using human
liver microsoms indicate that  neither Promethazine nor its metabolites are likely to affect
metabolism of other drugs metabolized by cytochrome P450 isoenzymes. The  interaction
with  ciprofloxacin  on  the  pharmacokinetics  of  a  single  dose  of promethazine was
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studied. The Cmax and AUC promethazine increased by 7-fold and 10 fold respectively.
These changes leads  to  decrease in blood pressure,  increased drowsiness  and increase in
psychomotor impairment. Promethazine delayed the Tmax of acetaminophen by 16minutes.
Consumption of alcohol with promethazine hydrochloride increases the side effects.
Indications             : Promethazine HCl is used in
 Allergies: Treatment of allergic conditions including some allergic reactions to drugs,
urticaria  and  allergic  contact  dermatitis,  and  allergic  reactions  to  insect  bites  and
stings. 
 Upper respiratory tract: Relief of excessive secretion in the upper respiratory tract as a
result of hay fever and allergic rhinitis. 
 Nausea  and  vomiting:  Antiemetic  for  vomiting  from  various  causes,  including
postoperative  vomiting,  irradiation  sickness,  drug  induced  nausea  and  motion
sickness. 
 Sedation: For short term use under the advice of a doctor or pharmacist. Do not use
for more than 7 to 10 consecutive days. 
 Other:  Promethazine  has  sedative  effects  and  can  be  used  in  the  symptomatic
management of measles and chicken pox. 
 Promethazine  can  be  used  as  a  preanaesthetic  medication  for  the  prevention  and
control of post operative vomiting.
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EXCIPIENT PROFILE
HYDROXYPROPYL METHYL CELLULOSE60
Non-proprietary Names : BP : Hypromellose
                                                JP : Hydroxypropylmethylcellulose
                                              PhEur : Hypromellosum
                                                USP : Hypromellose     
Synonyms :  Cellulose; Hydroxypropylmethyl Ether; Methocel; HPMC; 
                                                 Methylcellulose; Propyleneglycol ether; Pharmacoat, Benecel 
                                                 MHPC; hydroxypropyl methylcellulose; 
Chemical Name :  Cellulose, 2-hydroxypropylmethylether.
Molecular Weight     :  10,000 – 15,00,000.  
Structural Formula :  
Description :  Hypromellose is an odorless and tasteless, white or creamy 
                                                 white fibrous or granular powder
Functional Category :  Coating agent; film-former; rate-controlling polymer for
                                                 sustained release; stabilizing agent; suspending agent; tablet
                                                 binder; viscosity-increasing agent. 
Solubility          :  Soluble in cold water, insoluble in chloroform, ethanol and
                                                 ether, soluble in mixtures of ethanol and dichloromethane and
                                                 mixtures of methanol and dichloromethane.
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Typical Properties  
Acidity/Alkalinity :    pH = 5.5–8.0 for a 1% w/w aqueous solution.
Density          :   0.341 g/cm3
Density (tapped) :   0.557 g/cm3
Density (true)  :  1.326 g/cm3
Melting point   :  browns at 190–200oC; chars at 225–230oC.
Moisture content   : Hypromellose  absorbs  moisture  from  the  atmosphere;  the
amount of water absorbed depends upon the initial moisture content and the temperature and
relative humidity of the surrounding air.
Stability and Storage : It is a stable material, although it is hygroscopic after drying.
Solutions are stable at pH 3–11. Increasing temperature reduces the viscosity of solutions. It
undergoes  a  reversible  sol–gel  transformation  upon  heating  and  cooling,  respectively.
Hypromellose powder should be stored in a well-closed container, in a cool, dry place. 
Safety : It is generally regarded as a nontoxic and non-irritant material,
although excessive oral consumption may have a laxative effect.
Incompatibilities : Hypromellose  is  incompatible  with  some oxidizing agents.
Since it is nonionic, hypromellose will not complex with metallic salts or ionic organics to
form insoluble precipitates.
Applications : In oral products, hypromellose is primarily used as a tablet
binder,  in  film-coating,  and  as  a  matrix  for  use  in  extended-release  tablet  formulations.
Concentrations  between  2% and 5% w/w may be  used  as  a  binder  in  either  wet  or  dry
granulation processes. High-viscosity grades may be used to retard the release of drugs from
a matrix  at levels of 10–80% w/w in tablets and capsules.  Depending upon the viscosity
grade, concentrations of 2–20% w/w are used for film-forming solutions to film-coat tablets.
Lower-viscosity grades  are used in aqueous film-coating solutions,  while higher-viscosity
grades  are  used  with  organic  solvents.  Hypromellose  is  also  used  as  a  suspending  and
thickening agent in topical formulations. Hypromellose at concentrations between 0.45–1.0%
w/w may be added as a thickening agent to vehicles for eye drops and artificial tear solutions.
Hypromellose is also used as an emulsifier, suspending agent, and stabilizing agent in topical
gels  and  ointments.  As  a  protective  colloid,  it  can  prevent  droplets  and  particles  from
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coalescing  or  agglomerating,  thus  inhibiting  the  formation  of  sediments.  In  addition,
hypromellose is used in the manufacture of capsules, as an adhesive in plastic bandages, and
as  a  wetting agent  for  hard contact  lenses.  It  is  also widely used  in  cosmetics  and food
products.
GLYCERIN 60
Non proprietary name    :  BP : Glycerol
              JP : Concentrated glycerin
              PhEur : Glycerolum
              USP : Glycerin
Synonyms          : Croderol; E422; glycerine; Glycon G-100; Kemstrene; Optim;
                                            Pricerine; 1,2,3-propanetriol; trihydroxypropane glycerol.
Chemical Name     : Propane-1,2,3-triol
Empirical Formula  : C3H8O3 
Molecular Weight   : 92.09
Functional Category :Antimicrobial preservative; emollient; humectants; plasticizer;
  solvent; sweetening agent; tonicity agent.
Boiling point   : 2900C (with decomposition)
Density : 1.2656 g/cm3 at 15oC;
      1.2636 g/cm3 at 20oC;
      1.2620 g/cm3 at 25oC.
Flash point : 176oC (open cup)
Hygroscopicity   : hygroscopic
Melting point : 17.8oC
Osmolarity : a 2.6% v/v aqueous solution is iso osmotic with serum.
Description :  Glycerin is a clear, colorless, odorless, viscous, hygroscopic
liquid; it has a sweet taste, approximately 0.6 times as sweet as sucrose.
Applications : Glycerin  is  used  in  a  wide  variety  of  pharmaceutical
formulations including oral, otic, ophthalmic, topical, and parenteral preparations. In topical
pharmaceutical formulations and cosmetics, glycerin is used primarily for its humectant and
emollient properties. In parenteral formulations, glycerin is used mainly as a solvent. In oral
solutions,  glycerin  is  used  as  a  solvent,  sweetening agent,  antimicrobial  preservative and
viscosity-increasing agent. It  is also used as a plasticizer and in film coatings. Glycerin is
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additionally used in topical formulations such as creams and emulsions. Glycerin is used as a
plasticizer  of  gelatin  in  the  production  of  soft-gelatin  capsules  and  gelatin  suppositories.
Glycerin is employed as a therapeutic agent in a variety of clinical applications, and is also
used as a food additive.
Incompatibilities :  Glycerin may explode if mixed with strong oxidizing agents
such  as  chromium  trioxide,  potassium  chlorate,  or  potassium  permanganate.  In  dilute
solution, the reaction proceeds at a slower rate with several oxidation products being formed.
Black discoloration of glycerin occurs in the presence of light, or on contact with zinc oxide
or basic bismuth nitrate. An iron contaminant in glycerin is responsible for the darkening in
color of mixtures containing phenols,  salicylates, and tannin.  Glycerin forms a boric acid
complex, glyceroboric acid that is a stronger acid than boric acid.
Safety :  Adverse effects are mainly due to the dehydrating properties
of glycerin. Oral doses are demulcent and mildly laxative in action. Large doses may produce
headache,  thirst,  nausea,  and  hyperglycemia.  The therapeutic  parenteral  administration  of
very large glycerin doses, 70–80 g over 30–60 minutes in adults to reduce cranial pressure,
may  induce  hemolysis,  hemoglobinuria,  and  renal  failure.  Slower  administration  has  no
deleterious effects. Glycerin may also be used orally in doses of 1.0–1.5 g/kgbody-weight to
reduce  intraocular  pressure.  When used as  an  excipient  or  food additive,  glycerin  is  not
usually associated with any adverse effects and is generally regarded as a non-toxic and non-
irritant material.
Stability and Storage   : Glycerin  is  hygroscopic.  Glycerin  decomposes  on  heating,
with the evolution of toxic acrolein.  Mixtures of glycerin with water,  ethanol (95%), and
propylene  glycol  are  chemically  stable.  Glycerin  may  crystallize  if  stored  at  low
temperatures; the crystals do not melt until warmed to 200C. Glycerin should be stored in an
airtight container, in a cool, dry place.
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POLY ETHYLENE GLYCOL 400 60
Nonproprietary Names :   BP : Macrogols
                                               JP : Macrogol 400
                                               PhEur : Macrogola
                                               USPNF : Polyethylene glycol
Synonyms         : Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG;
   Pluriol E; polyoxyethylene glycol.
Chemical Name :  a-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl)
Empirical Formula : HOCH2 (CH2OCH2)mCH2OH 
  Where m - averagenumber of oxyethylene groups
Description      : Liquid grades (PEG 200–600) occur as clear, colourless or  
   slightly yellow-coloured, viscous liquids. They have a slight 
   but characteristic odour and a bitter, slightly burning taste. 
Functional Category  : Ointment base; plasticizer;  solvent; suppository base;  tablet
and   capsule lubricant.
Density       : 1.11–1.14 g/cm3 at 25oC for liquid PEGs;
Flash point        : 238oC for PEG 400.
Freezing point   : 4–8oC for PEG 400;
Moisture content  : liquid polyethylene glycols are very hygroscopic, 
Solubility                 : all  grades  of  polyethylene  glycol  are  soluble in  water  and
miscible in all proportions with other polyethylene glycols. Liquid polyethylene glycols are
soluble in acetone, alcohols, benzene, glycerin, and glycols. 
Applications          : Polyethylene glycols (PEGs) are widely used in a variety of
pharmaceutical  formulations  including  parenteral,  topical,  ophthalmic,  oral,  and  rectal
preparations. It  has been used experimentally in biodegradable polymeric matrices used in
controlled-release systems. Polyethylene glycols are stable, hydrophilic substances that are
essentially  non  irritant  to  the  skin.  They do  not  readily  penetrate  the  skin,  although the
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polyethylene glycols are water-soluble and are easily removed from the skin by washing,
making them useful as ointment bases. 
Mixtures of polyethylene glycols can be used as suppository bases, for which they
have many advantages over fats. Aqueous polyethylene glycol solutions can be used either as
suspending agents or to adjust the viscosity and consistency of other suspending vehicles.
When used in conjunction with other emulsifiers, polyethylene glycols can act as emulsion
stabilizers. Liquid polyethylene glycols are used as water-miscible solvents for the contents
of soft gelatin capsules. In concentrations up to approximately 30% v/v, PEG 300 and PEG
400 have been used as the vehicle for parenteral dosage forms.
The presence of polyethylene glycols in film coats, especially of liquid grades, tends
to increase their water permeability and may reduce protection against low pH in enteric-
coating films. Polyethylene glycols are useful as plasticizers in microencapsulated products to
avoid rupture of the coating film when the microcapsules are compressed into tablets.
Polyethylene glycols have been used in the preparation of urethane hydrogels, which
are used as controlled-release agents. It has also been used in insulin-loaded microparticles
for  the  oral  delivery  of  insulin;  it  has  been  used  in  inhalation  preparations  to  improve
aerosolization;  polyethylene  glycol  nanoparticles  have  been  used  to  improve  the  oral
bioavailability of cyclosporine; it has been used in selfassembled polymeric nanoparticles as
a drug carrier; and copolymer networks of polyethylene glycol grafted with poly (methacrylic
acid) have been used as bioadhesive controlled drug delivery formulations.
Incompatibilities          : The  chemical  reactivity  of  polyethylene  glycols  is  mainly
confined to the two terminal hydroxyl groups, which can be either esterified or etherified.
However, all grades can exhibit some oxidizing activity owing to the presence of peroxide
impurities and secondary products formed by autoxidation. Liquid and solid polyethylene
glycol grades may be incompatible with some coloring agents. The antibacterial activity of
certain antibiotics is reduced in polyethylene glycol bases, particularly that of penicillin and
bacitracin.
The preservative efficacy of the parabens may also be impaired owing to binding with
polyethylene glycols. Physical effects caused by polyethylene glycol bases include softening
and liquefaction in mixtures with phenol, tannic acid, and salicylic acid.  Discoloration of
sulfonamides and dithranol can also occur and sorbitol may be precipitated from mixtures.
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Plastics, such as polyethylene, phenolformaldehyde, polyvinyl chloride, and cellulose-ester
membranes (in filters) may be softened or dissolved by polyethylene glycols. Migration of
polyethylene  glycol  can occur from tablet  film coatings,  leading to  interaction with core
components.
Safety                 :  Generally,  PEGs are  regarded  as  nontoxic  and  non-irritant
materials. Adverse reactions to polyethylene glycols have been reported, the greatest toxicity
being with glycols of low molecular weight. However, the toxicity of glycols is relatively
low. Polyethylene glycols administered topically may cause stinging, especially when applied
to mucous membranes.
Hypersensitivity reactions to polyethylene glycols applied topically have also been
reported, including urticaria and delayed allergic reactions. The most serious adverse effects
associated  with  polyethylene  glycols  are  hyperosmolarity,  metabolic  acidosis,  and  renal
failure following the topical use of polyethylene glycols in burpatients. Topical preparations
containing polyethylene glycols should therefore be used cautiously in patients with renal
failure,  extensive  burns,  or  open  wounds.  Oral  administration  of  large  quantities  of
polyethylene glycols can have a laxative effect.
Liquid  polyethylene  glycols  may  be  absorbed  when  taken  orally.  Absorbed
polyethylene glycol is excreted largely unchanged in the urine, although polyethylene glycols
of low molecular weight may be partially metabolized. In parenteral products, the maximum
recommended concentration of  PEG 300 is  approximately 30% v/v as haemolytic effects
have been observed at concentrations greater than about 40% v/v.
Stability               : Polyethylene  glycols  are  chemically  stable  in  air  and  in
solution,  although  grades  with  a  molecular  weight  less  than  2000  are  hygroscopic.
Polyethylene  glycols  do  not  support  microbial  growth,  and  they  do  not  become  rancid.
Polyethylene  glycols  and  aqueous  polyethylene  glycol  solutions  can  be  sterilized  by
autoclaving, filtration, or gamma irradiation. Ideally, sterilization should be carried out in an
inert atmosphere. Oxidation of polyethylene glycols may also be inhibited by the inclusion of
a suitable antioxidant.  Oxidation may occur if  polyethylene glycols are exposed for  long
periods  to  temperatures  exceeding  50oC.  However,  storage  under  nitrogen  reduces  the
possibility of oxidation.
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Storage Conditions  : Polyethylene  glycols  should  be  stored  in  well-closed
containers in a cool, dry place. Stainless steel, aluminium, glass, or lined steel containers are
preferred for the storage of liquid grades.
PROPYLENE GLYCOL60
Nonproprietary Names   : BP : Propylene glycol
     JP : Propylene glycol
     PhEur : Propylenglycolum
     USP : Propylene glycol
Synonyms            :  1,2-Dihydroxypropane; E1520; 2-hydroxypropanol; methyl
                                              ethylene glycol; methyl glycol; propane 1,2-diol.
Chemical Name  :  b1,2-Propanediol, (þ)-1,2-Propanediol
Empirical Formula :  C3H8O2
Molecular Weight    :  76.09
Typical Properties : Boiling point : 188oC
Density : 1.038 g/cm3 at 20oC
Flash point : 99oC (open cup)
Melting point : -59oC
Osmolarity :  2.0% v/v  aqueous  solution  is  isoosmotic  
   with serum.
Description  : Propylene  glycol  is  a  clear,  colorless,  viscous,  practically
odorless liquid with a sweet, slightly acrid taste resembling that of glycerin.
Functional Category :  Antimicrobial  preservative;  disinfectant;  humectant;
plasticizer; solvent; stabilizer for vitamins; water-miscible cosolvent.
Solubility  : miscible with acetone, chloroform, ethanol (95%), glycerin,
and water; soluble at 1 in 6 parts of ether; not miscible with light mineral oil or fixed oils, but
will dissolve some essential oils.
Applications  :  Propylene  glycol  has  become  widely  used  as  a  solvent,
extractant,  and  preservative  in  a  variety  of  parenteral  and  nonparenteral  pharmaceutical
formulations.  It  is  a  better  general  solvent  than glycerin  and dissolves  a  wide variety of
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materials, such as corticosteroids, phenols, sulfa drugs, barbiturates, vitamins (A and D), most
alkaloids, and many local anesthetics. As an antiseptic it is similar to ethanol, and against
molds it is similar to glycerin and only slightly less effective than ethanol. Propylene glycol is
commonly used as a plasticizer in aqueous film-coating formulations. Propylene glycol is
also used in cosmetics and in the food industry as a carrier for emulsifiers and as a vehicle for
flavours in preference to ethanol, since its lack of volatility provides a more uniform flavor.
Incompatibilities: Propylene glycol is incompatible with oxidizing reagents such
as potassium permanganate.
Safety  : Propylene glycol is generally regarded as a relatively nontoxic
material. In topical preparations, propylene glycol is regarded as minimally irritant, although
it is more irritant than glycerin. Some local irritation is produced upon application to mucous
membranes  or  when it  is  used under  occlusive conditions.  Parenteral  administration may
cause pain or irritation when used in high concentration. Propylene glycol is estimated to be
one-third as intoxicating as ethanol, with administration of large volumes being associated
with adverse effects most commonly on the central nervous system, especially in neonates
and  children.  Other  adverse  reactions  reported,  though  generally  isolated,  include:
ototoxicity; cardiovascular effects; seizures; and hyperosmolarity and lactic acidosis, both of
which occur most frequently in patients with renal  impairment. Adverse effects are more
likely  to  occur  following  consumption  of  large  quantities  of  propylene  glycol  or  on
adminstration to neonates, children under 4 years of age, pregnant women, and patients with
hepatic or renal failure. Adverse events may also occur in patients treated with disulfiram or
metronidazole.  Formulations  containing  35%  propylene  glycol  can  cause  hemolysis  in
humans. In animal studies, there has been no evidence that propylene glycol is teratogenic or
mutagenic. 
Stability  : At  cool  temperatures,  propylene glycol  is  stable in  a  well-
closed container,  but at high temperatures, in the open, it  tends to oxidize,  giving rise to
products such as propionaldehyde, lactic acid, pyruvic acid, and acetic acid. Propylene glycol
is chemically stable when mixed with ethanol (95%), glycerin, or water; aqueous solutions
may be sterilized by autoclaving. Propylene glycol is hygroscopic and should be stored in a
well-closed container, protected from light, in a cool, dry place.
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EXPERIMENTAL METHOD
ANALYTICAL METHOD DEVELOPMENT
Identification of λmax for Promethazine Hydrochloride
Promethazine hydrochloride was accurately weighed and dissolved in 6.8 phosphate
buffer and sequent dilution was made to get the required concentrations (10µg/ml). The wave
length of  maximum absorbance  (λmax) of  this  clear  solution was determined from 200-
400nm. And 6.8 pH buffer was used as blank. 
Construction of Standard Curve for Promethazine Hydrochloride:
Preparation of reagents:
Phosphate buffer 6.8: 
Placed 0.2 M potassium di hydrogen phosphate in 200 mL volumetric flask, add 16.4
mL of 0.2M sodium hydroxide and make volume up to 200mL with distilled water.58
A) Preparation of 0.2 M potassium dihydrogen phosphate:
136.09 g of potassium dihydrogen phosphate in 1000 mL of water.58
B) Preparation of 0.2 M sodium hydroxide:
8g of sodium hydroxide in 1000 mL of water.58
Procedure:
Preparation of stock solution
Promethazine hydrochloride 50mg was dissolved in water 50 ml. From this solution 1
ml was pipetted and diluted with water up to 10ml, from this solution 5 ml was pipetted and
diluted with water up to 50ml mark this solution as stock solution.
Preparation of sample solution:
             Further dilution was carried out taking 2, 4, 6, 8, 10 and made up to 10 ml to obtain
the concentration of 2, 4, 6, 8, 10 µg/ml respectively. The absorbance was measured at 249
nm against the respective blank solution using UV visible spectrophotometer Systronics 118.
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The standard curves were plotted by putting the known concentration on X- axis and the ob-
tained absorbance on Y- axis.
In pH 6.8 (Phosphate buffer) and pH 7.4 (Phosphate buffer)
Preparation of stock solution
Promethazine hydrochloride 50mg was dissolved in water 50 ml. From this solution 1
ml was pipetted and diluted with water up to 10ml. From this solution 5 ml was pipetted and
diluted with water up to 50ml mark this solution as stock solution.
Preparation of sample solution:
Further dilution was carried out taking 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and made up to 10 ml
to obtain the concentration of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 µg/ml respectively. The absorbance
was measured at 249nm against the respective blank solution using UV visible spectrophoto-
meter. The standard curves were plotted by putting the known concentration on X- axis and
the obtained absorbance on Y- axis.
DRUG POLYMER COMPATIBILITY STUDIES
Infrared spectroscopy for pure drug Promethazine hydrochloride and polymers used
for formulation were testify to check the intactness of drug and polymer in the formulation
using Perkin Elmer model furrier transform infrared spectrometer by KBr disk method.
FABRICATION OF DOSAGE FORM
Product  optimization  was  done  after  the  evaluation  of  polymer  and  plasticizer
combination  and  concentration  by  literature  studies  and  drug  compatibility  studies.
Compositions of the formulations given in table no: 4.
Preparation of Patches:
Buccal patches of Promethazine hydrochloride were prepared using solvent casting
method. The formulation code and their respective composition are given in the table no 4.
Accurately weighed quantity of polymers HPMC K4M and HPMC 15cps were added to the
specified mentioned amount of double distilled water with continuous stirring until semisolid
solution formed. These polymer solutions were kept overnight for completion of swelling and
removal of air bubbles. Accurately weighed quantity of drug was dissolved in slurry with
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continuous stirring and the specified quantity of plasticizers was added. The prepared thick
solution was poured on petriplates of 8cm diameter and dried at 50oC for 60 min in mi-
crowave oven followed by keeping in vacuum oven at 37o for 24hrs. After drying, patches
were removed with the help of sharp blade and kept in desiccator overnight. The prepared
patches were cut into small circular patches of 2.6 cm diameter containing 10 mg of drug us-
ing a die-cutter. 
Table No: 4 Compositions of Formulations
INGREDIENTS
Promethazine
HCl
(mg)
HPMC
K4M
(mg)
HPMC
15cps
(mg)
Glyceri
n (mg)
PEG
400
(mg)
Propylene
glycol
(mg)
Distilled
water
to makeup
to
F
O
R
M
U
L
A
T
I
O
N
C
O
D
E
F1 100 400 - 50 - - 20ml
F2 100 400 - 100 - - 20ml
F3 100 400 - 200 - - 20ml
F4 100 500 - 62.5 - - 20ml
F5 100 500 - 125 - - 20ml
F6 100 500 - 250 - - 20ml
F7 100 400 - - 200 - 20ml
F8 100 400 - - - 200 20ml
F9 100 500 - - 250 - 20ml
F10 100 500 - - - 250 20ml
F11 100 - 2000 1000 - - 20ml
F12 100 - 2000 - 1000 - 20ml
F13 100 - 2000 - - 1000 20ml
PHYSICO-CHEMICAL EVALUATION OF PATCHES
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Thickness
All the batches were evaluated for thickness by using calibrated  Dial gauge. Three
samples  from all  the  batches  were  evaluated  for  thickness  and  the  average  and  standard
deviation were calculated.
Uniformity of weight
            Each patch was weighed individually on electronic balance and average weight of
three patches was found. 
Drug content estimation
The unit dose of the prepared patches were dissolved in 100ml of pH 6.8 Phosphate buffer
and the amount of Promethazine hydrochloride was determined spectro photometrically at
249 nm.33
Folding endurance
The folding endurance was measured manually for the prepared patches. A strip of
patch was cut and repeatedly folded at the same place till it broke. The number of times the
patch  could  be  folded  at  the  same  place  without  breaking  gave  the  value  of  folding
endurance.35
Surface pH
Patches were left to swell for 10min in Petri-dish containing 1ml of distilled water.
The surface pH was measured by means of pH paper placed on the surface of the swollen
patches. 35
Swelling studies
The patches were cut into 1×1 cm2 size and weight was noted. The patches were kept
on  pre  weighed  cover  slips  of  1×1cm2  sizes  separately and  total  weight  was  noted.  The
patches  with cover slips were placed in separate petri-dishes containing 10ml of distilled
water. After 30 min. the patches with cover slips were taken out and excess water on the
bottom of the cover slips was wiped with tissue paper and weight was noted.
                Swelling index = W1 - W0 / W0
                            Where, W1 = final weight             W0 = initial weight
TENSILE STRENGTH
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Tensile strength of the patch was determined with TA.XT plus texture analyzer. The A/TG
consists of two load cell grips (Fig.5). The lower one is fixed and the upper one is movable.
The test patch was fixed between the cell grips and the tensile force was gradually applied till
the patch broke. The reports of the tests were obtained directly from the software Exponent
light.62-63,66
TA Settings :   
Accessory : Tensile Grips (A/TG) using 5kg load cell
Mode           : Measure Force in Tension
Pre-Test Speed : 1.0 mm/s
Test Speed     : 1.0 mm/s
Post-Test Speed : 10.0 mm/s
Distance  : 15mm
Trigger Type  : Auto - 5g
Sample Preparation : Cut the patches into strips of 10×20 mm size.
Test Set-Up : Upper tensile grip was attached to the load cell carrier and secured
the lower tensile grip to the base of the machine. Tensile grips were calibrated to start from a
set distance (20mm) apart for each test and saved this as a preset position using the Probe
Preset icon in the Project window.
Upper grip moved to a higher sample loading position so that when the sample is
attached to the upper  grip it  is  free to hang without contact  with the lower grip  and the
patches were inserted and tighten the grip to secure the sample. Click on T.A. - Move Probe
and then Tools - Tare (to zero the weight of the upper grip and sample). Move to the Preset
start position by clicking Memory - Location 1 and click on the required position. Sample
was  attached  to  the  lower  grip.  The  slack  in  the  sample  between  the  jaws  should  be
minimized without stretching the sample when doing this.
Probe Calibration : The grips lowered, so that they were close together. Clicked on T.A.
then CALIBRATE PROBE and specified the distance that the grips to start apart from each
other for each test (20mm).
Observations : Clicked OK button to begin test and the graph proceeded to plot the
effect  on the patches under  tension. When the elastic  limit  is  exceeded the patch snaped
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(observed as the maximum tension force). The greater the distance at the break point the
more extensible the sample.
Data Analysis :  Once  tests  have  been  performed,  values  of  particular  interest  for
sample analysis can be automatically obtained by a MACRO.
MUCOADHESION STUDY
Mucoadhesive  strength  of  the  patch  was  determined  with  TA.XT  plus  texture
analyzer. Probe  A/MUC is used for the test (Fig.6).  It  consists of two load cell grips. The
lower one is fixed and the upper one is movable. The test patch was fixed in the upper moved
probe and the goat buccal mucosa was fixed in the lower cell which is moistened with the
phosphate buffer pH 6.8. The Mucoadhesion Rig support ring should expose the tissue to the
medium, whilst holding the tissue fast during the withdrawal phase of the test. The test patch
was stucked to the lower side of the buccal mucosa. The force required to detach the patches
from the mucosal surface gave the measure of mucoadhesive strength. 62-64
 TA Settings :
Accessory : Mucoadhesion Rig (A/MUC) using 50 kg load cell
Option  : Adhesive Test
Pre-Test Speed : 0.5 mm/s
Test Speed : 0.1 mm/s
Post-Test Speed : 0.1 mm/s
Trigger Type : Auto - 3g
Tare Mode : Auto
Force applied : 3.5N
Contact time : 120 sec.
Test Set-up : The test conditions were maintained i.e, phosphate buffer 6.8 at 370C
by use of a thermostatically controlled magnetic heater/stirrer. Prior to testing the tissue was
allowed to equilibrate with the medium for 15 minutes. Common probe sizes and dimensions
used  for  bioadhesive  testing  were  acrylic  cylinders  with  a  diameter  of  10  mm.  Patches
attached to the underside of the 10mm probe with a double-sided adhesive tape.
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Sample Preparation Alternatives
A fixed volume of buffer pipetted onto the mucosa to standardise the hydration prior
to  testing. The  force  needed  to  detach  the  dosage  form  was  recorded  as  a  function  of
elongation  and  both maximum strength  and  area  under  the  force/time curve  was  usually
obtained. The results were converted into work of adhesion and then represented as a mean
value with standard deviation.
Data Analysis : Once tests have been performed sample analysis can be automatically
obtained by a MACRO
IN-VITRO DISSOLUTION STUDIES
The release study was carried out in a USP 24 dissolution apparatus type VI (six-
station dissolution apparatus, Hanson Research Corp., USA). The dissolution medium was
900 mL. Phosphate buffer, pH 6.8, maintained at 370C and kept in the USP dissolution flask.
The patch was fixed to the central axis, which rotated at 50 rpm. Filtered samples (5 ml.)
were manually collected at intervals of 30min up to 3hrs. The samples were compensated
with an equal volume of phosphate buffer kept at the same temperature. The concentration of
drug released in the medium was assayed Spectrophotometrically at 249 nm after suitable
dilution with the dissolution medium when necessary.33
Dissolution parameters
Dissolution Medium : Phosphate buffer pH 6.8
Paddle speed : 50 rpm
Apparatus : Dissolution apparatus Type USP VI (cylinder Apparatus) (Fig.7) 
Temperature : 37ºC ± 0.5ºC
Withdrawal time : 3 hrs with 30 mins interval  
Volume withdrawn : 5 ml
EX VIVO DRUG PERMEATION STUDY
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             Ex-vivo study of Promethazine hydrochloride permeation through goat buccal
mucosa was performed using a Diffusion cell. Fresh Goat buccal mucosa was obtained from a
local  slaughter house .Goat buccal  mucosa mounted between the donor compartment and
receptor compartment so that the smooth surface of the mucosa faced the donor compartment.
The patches were placed on the mucosa and the donor compartment was filled with 15ml of
phosphate  buffer  pH  6.8.  The  donor  compartment  fixed  such  that  it  touches  surface  of
receptor compartment (15ml capacity). The receptor compartment was filled with phosphate
buffer pH 7.4. The assembly was maintained at 37o  C and stirred magnetically. 1ml sample
was withdrawn at specific time intervals and suitable dilutions were done and analyzed for
drug content at 249nm in UV-visible spectrophotometer.44
Diffusion parameters
Donor compartment : Phosphate buffer pH6.8
Receptor compartment : Phosphate buffer pH7.4
Apparatus :  Diffusion cell (Fig.8)
Withdrawal time : 3 hrs with 30 mins interval
Volume withdrawn : 1mL
Drug release and drug diffusion study was analyse by following method:
U.V Spectrophotometry : The sample withdraw was analyse by U.V Spectrophotometer
IN VIVO COMPATIBILITY STUDY
Informed consent  was  obtained  from all  human volunteers  before  conducting study.  The
study  was  conducted  on  10  human  volunteers.  Selected  formulation  was  given  to  the
volunteers and asked them to report for any irritation, discomfort, local anaesthetic effect,
heaviness and for the overall acceptance.33
Figure no: 5 Tensile strength analysis                  Figure no: 6 Mucoadhesion study with
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                       with Texture analyser.                                              Texture analyser.
                                     
Figure no: 7 In vitro Drug release study using Dissolution apparatus USP VI 
Figure no: 8 Ex-vivo drug permeation study through Goat buccal mucosa using 
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                       Diffusion cell
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RESULTS AND DISCUSSION
ANALYTICAL METHOD DEVELOPMENT
Construction of Standard Curve for Promethazine Hydrochloride
The wave length of maximum absorbance of drug was found to be 249 nm and the
drug solution was found to obey Beer’s law in the range of 1-10µg/ml at 249 nm against 6.8
pH buffer as blank. The values are given in table no: 5 and standard graphs in figure 9&10.
Table No: 5 Standard Curve of Promethazine hydrochloride Absorbance of
Promethazine Hydrochloride at Different pH
Sl.no Concentration(µg/ml)
Absorbance at 249 nm
pH 6.8 pH 7.4
1 0 0 0
2 1 0.112 0.101
3 2 0.154 0.123
4 3 0.268 0.214
5 4 0.303 0.294
6 5 0.414 0.327
7 6 0.486 0.421
8 7 0.531 0.491
9 8 0.596 0.513
11 10 0.711 0.697
Figure No: 9 Calibration Curve for Promethazine hydrochloride in pH 6.8
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 Phosphate Buffer at 249nm
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Figure No: 10 Calibration Curve for Promethazine hydrochloride in pH 7.4       
Phosphate buffer at 249nm
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DRUG-POLYMER COMPATIBILITY STUDY
FTIR analysis  for  drug, polymers  and the drug polymer mixtures  were done. The
reports were given as figures 11-15 and in tables 6-10.
Figure No: 11 Promethazine hydrochloride FTIR
Table No: 6 Promethazine hydrochloride FTIR
Wave number in cm-1 Characteristic band
3426.80 N-H Stretching
3057.88 C-H Stretching aromatic
758.80 C-S deformation
1569.00 C=C
1455.51 C=C
1274.47 C-N Stretching
1225.88 C-N Stretching
856.32 C-H deformation
1379 C-H deformation
1569.00 N-H deformation
1379.89 C-S Stretching
Figure No: 12 FTIR Studies for HPMC K4M
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Table No: 7 FTIR Studies for HPMC K4M
Wave number in cm-1 Characteristic band
3465.85 OH Stretching
2930.82 C-H Stretching
1062.68 C-O-C Stretching
1655.10 C-O Stretching
946.255 C-H deformation 
1460.01 C-H deformation
Figure No: 13 FTIR Studies for HPMC 15cps
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Table No: 8 FTIR Studies for HPMC 15cps
Wave number in cm-1 Characteristic band
3466.31 OH Stretching
2929.45 C-H Stretching
1056.81 C-O-C Stretching
1655.28 C-O Stretching
941.77 C-H deformation 
1465.93 C-H deformation
Figure No: 14 FTIR studies for Promethazine hydrochloride and HPMC K4M blend
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Table No: 9 FTIR studies for Promethazine hydrochloride and HPMC K4M Blend
Wave number in cm-1 Characteristic band
3465.37 O-H Stretching
3465.37 N-H Stretching
2931.39 C-H Stretching
1655.12 C-O Stretching
1126.74 C-O-C Stretching
1039.84 C-O-C Stretching
856.20 C-H deformation
933.07 C-H deformation
1379.04 C-S Stretching
758.80 C-S deformation
1456.19 C=C Stretching
1568.31 C=C Stretching
1224.97 C-N Stretching
1256.87 C-N Stretching
1568.31 N-H deformation
Figure No: 15 FTIR studies for Promethazine hydrochloride and HPMC 15cps blend
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Table No: 10 FTIR studies for Promethazine hydrochloride and HPMC 15cps Blend
Wave number in cm-1 Characteristic band
3465.97 O-H Stretching
3465.97 N-H Stretching
2930.08 C-H Stretching
1657.81 C-O Stretching
1126.58 C-O-C Stretching
1038.73 C-O-C Stretching
856.20 C-H deformation
931.92 C-H deformation
1380.29 C-S Stretching
759.03 C-S deformation
1455.73 C=C Stretching
1588.75 C=C Stretching
1224.91 C-N Stretching
1256.87 C-N Stretching
1588.75 N-H deformation
The results of FTIR showed that there was no interaction between polymers and drug
as all individual peaks for the drug and polymers were obtained in the mixture.
DEVELOPMENT OF FORMULATIONS:
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The thin films of Promethazine showed unpleasant anaesthetic effect in tongue during
preliminary works. The drug content of unit patch (2.6cm diameter) for all the batches were
10  mg  Promethazine  hydrochloride  which  was  in  accordance  with  amount  used  in
‘Phenergan’ (Sanofi aventis). The formulations F1, F2, F3 were prepared with HPMC K4M
2% with glycerine 12.5%, 25% and 50% to the dry weight of polymer respectively. F7 & F8
were  prepared  using  2%  of  HPMC  K4M  with  different  plasticizers  like  PEG-400  &
Propylene  glycol  50% to the  dry weight  of  polymer.  The formulations  F4,  F5,  F6  were
prepared with HPMC K4M 2.5% with glycerine 12.5%, 25% and 50% to the dry weight of
polymer respectively. F9 & F10 were prepared using 2.5% of HPMC K4M with different
plasticizers  like  PEG-400  &  Propylene  glycol  50%  to  the  dry  weight  of  polymer.
Formulations  F11,  F12,  F13  were  prepared  using  10%  of  HPMC  15  cps  and  different
plasticizers like glycerine, PEG-400 and Propylene glycol 50% to the dry weight of polymer
(Table 4). The drying process was done in microwave oven at 50oC to avoid any degradation
to drug when subjected to high temperature.
PHYSICOCHEMICAL EVALUATIONS
 All  physicochemical  parameters  of  the  prepared  buccal  patches  are  given  in  the
Table no.11.
Weight:
Weight of patches was ranging from 54.09±0.6 to 311.12±0.6 mg. Weight of patches
was  found to  be  increasing  proportion  of  polymer  and  plasticizer.  But  there is  no much
difference in weight of the patches with different plasticizer in same proportion (Table 11).
Thickness:
Thickness of the all formulated patches was found to be in the range of 77.67±0.33 to
424.33±2µm. As the total amount of polymer increases the thickness of the patches were
found to be increased. Thickness also increased with increase in concentration of plasticizer
(Table 11).
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Folding endurance:
Folding endurance is the index of ease of handling the patches. As the amount of
polymer increases the folding endurance was found to be increased. Plasticizer increases the
flexibility of the patches so the folding endurance also found to be increased. But there is no
marked change in folding endurance with different type of plasticizers. Folding endurance for
the patches was found to be 562±2 to 746±3. All patches exhibited folding endurance above
500 proving the flexible nature of the patch (Table 11). 
Surface pH:
Surface pH for all batches was between 5.5 to 6.0 which were due to pH of the drug
solution as well as the polymer, hence no mucosal irritations was expected and ultimately
achieves patient compliance (Table 11).
Drug content:
All the batches of the patches contain 9.88±0.21 to 10.13±0.01 mg of drug which
indicate that  there is  no loss  of  drug during preparation of  the patch (Table 11).  All  the
batches of the patches exhibit drug content within limit 98.8 to 101.3 % which is within the
desirable range due to the equal distribution of drug in the solution (Table 11).
Swelling studies:
Swelling index shows the moisture uptake and swelling behavior of buccal patches.
All the patches were subjected to swelling studies. The results indicated that all the patches
exhibited appreciable swelling nature within 30 min. The buccal patches with 10 % HPMC
15cps showed highest swelling index and also the swelling index increasing with polymer
concentration for HPMC K4M. Also it increases with increasing content of glycerine. There
is no marked change in swelling nature for patches with 50% of PEG 400 and Propylene
glycol when compared with glycerine (Table 11). 
Table No: 11 Physicochemical Evaluations of Buccal Patches.
Batch
no.
Weight ( mg)
(n=3)
Thickness
(µm)
(n=3)
Folding
endurance
(n=3)
Surface
pH
(n=3)
Swelling
index
Drug content
(mg)
(n=3)
F-1 54.09±0.6 77.67±0.33 562±2 6 20.69 10.08±0.09
F-2 61.38±0.3 91.33±0.89 614±2 6 28.35 10.12±0.04
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F-3 71.94±0.7 107.67±0.57 731±3 6 32.59 10.08±0.08
F-4 69.57±0.8 93.33±0.64 628±1 6 33.99 10.05±0.07
F-5 74.38±0.2 115.67±0.97 689±2 6 32.73 10.06±0.08
F-6 86.78±0.5 129.00±0.85 738±3 6 30.52 9.88±0.21
F-7 72.26±0.6 111.67±0.69 725±3 5.5 33.19 10.02±0.04
F-8 70.94±0.7 114.00±0.83 729±2 5.5 37.42 10.02±0.03
F-9 84.78±0.5 131.33±0.76 746±3 5.5 35.94 10.07±0.06
F-10 87.78±0.3 132.33±0.83 741±3 5.5 38.07 10.06±0.05
F-11 309.39±0.4 380.67±1 678±2 6 47.41 9.92±0.03
F-12 315.41±0.8 372.67±1 684±2 5.5 49.65 10.13±0.01
F-13 311.12±0.6 424.33±2 681±2 5.5 43.76 10.08±0.02
Tensile strength
The tensile strength of the patches was tested in TA.XT plus texture analyser and the
results are summarised in table no: 12 and figures 16-20.
Table no: 12 Tensile strength and Extensibility of the patches.
FORMULATION CODE EXTENSIBILITY (mm)Elongation at break
FORCE
(N)
TENSILE
STRENGTH
(MPa)
HPMC K4M 2%,
Glycerine 12.5% F1 5.481 23.67 30.35
HPMC K4M 2%,
Glycerine 25% F2 5.014 19.19 21.08
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HPMC K4M 2%,
Glycerine 50% F3 14.588 21.51 19.91
HPMC K4M 2.5%,
Glycerine 12.5% F4 7.871 29.73 31.8
HPMC K4M 2.5%,
Glycerine 25% F5 11.218 30.23 26.06
HPMC K4M 2.5%,
Glycerine 50% F6 14.876 35.40 27.44
HPMC K4M 2%,
PEG400 50% F7 19.397 26.64 23.78
HPMC K4M 2%,
PG 50% F8 3.289 17.63 15.46
HPMC K4M 2.5%,
PEG400 50% F9 22.344 39.76 30.33
HPMC K4M 2.5%,
PG 50% F10 11.503 38.77 29.37
HPMC 15cps 2%,
Glycerine 50% F11 17.723 72.11 18.92
HPMC 15cps 2%,
PEG400 50% F12 4.116 49.55 13.28
HPMC 15cps 2%,
PG 50% F13 14.803 26.50 6.25
Tensile strength and extensibility of the patches with HPMC K4M is higher compared
to patches with HPMC 15cps. Extensibility of the patches increased with increase in polymer
concentration and also with increase in the glycerine content. There is no significant effect
with PEG 400 and Propylene glycol on extensibility and tensile strength of the patches. The
flexibility and tensile strength increases with increasing amount of plasticizer (Table no: 12
and figures 16-20).
Figure no: 16 Tensile strength of Formulations F1, F2 & F3
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Figure no: 17 Tensile strength of Formulations F4, F5 & F6
Figure no: 18 Tensile strength of Formulations F7 & F8
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Figure no: 19 Tensile strength of Formulations F9 & F10
Figure no: 20 Tensile strength of Formulations F11, F12 & F13
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EVALUATION OF MUCOADHESION
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Mucoadhesive  strength  for  all  the  prepared  batches  on  Goat  buccal  mucosa  was
determined using TA.XT plus Texture analyser and results were given in table no: 13 and
figures 21-33.
Table: 13 Mucoadhesive strength of the buccal patches of Promethazine HCl.
BATCH NO:
ADHESIVE
FORCE(N)*
WORK OF
ADHESION*
(N.SEC)
DEBONDING
DISTANCE*
(mm)
F1 0.1951 1.667 1.688
F2 0.0196 0.0294 0.468
F3 0.174 0.595 1.116
F4 1.4562 6.251 4.340
F5 0.1997 1.693 4.340
F6 0.965 3.444 2.088
F7 0.5225 1.993 3.712
F8 0.2113 1.335 2.696
F9 0.0894 1.173 3.443
F10 0.6166 2.292 1.453
F11 0.0848 1.744 4.641
F12 1.238 3.550 4.926
F13 0.459 0.664 2.431
*The functional parameters fixed were 3.5N force applied and 120 sec. contact time.
The  adhesive  force  of  the  patches  was  found  to  be  varying  with  thickness  and
swelling  of  the  patches.  Patches  with  PEG  400  and  Propylene  glycol  have  poor
mucoadhesion.  Formulations  F3,  F6  and  F11  i.e,  with  50%  of  glycerine  showed  good
mucoadhesion. Hence glycerine can be used as plasticizer for good mucoadhesion. 
Mucoadhesive force increases with an increase in the molecular weight of polymer.
Too great degree of swelling results in slippery mucilage and can be easily removed from the
substrate. It is a hindrance to the adhesion polymers grafting onto the preformed network; and
the  inclusion  of  adhesion  promoters  in  the  formulation  (freepolymer).  Thicker  patches
remove water from the adhesive joint giving a suboptimal concentration required for effective
adhesion  with  biological  substrate.  Thinner  patches  have  a  lesser  capacity  for  water
sequestering and give a more hydrated surface.
Figure no: 21 Graph of mucoadhesion of F1
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Figure no: 22 Graph of mucoadhesion of F2
Figure no: 23 Graph of mucoadhesion of F3
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Figure no: 24 Graph of mucoadhesion of F4
Figure no: 25 Graph of mucoadhesion of F5
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Figure no: 26 Graph of mucoadhesion of F6
Figure no: 27 Graph of mucoadhesion of F7
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Figure no: 28 Graph of mucoadhesion of F8
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Figure no: 29 Graph of mucoadhesion of F9
Figure no: 30 Graph of mucoadhesion of F10
Figure no: 31 Graph of mucoadhesion of F11
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Figure no: 32 Graph of mucoadhesion of F12
Figure no: 33 Graph of mucoadhesion of F13
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IN-VITRO DRUG RELEASE STUDY
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The in vitro drug release studies were done for all the batches in Phosphate buffer pH
6.8 using Dissolution apparatus USP VI (cylinder apparatus). The release data were given in
table no: 14 and figures 34-38.
Dissolution Parameters
Dissolution Medium : Phosphate buffer pH 6.8
Paddle speed : 50 rpm
Apparatus : Dissolution apparatus Type USP VI (cylinder Apparatus)
Temperature : 37ºC ± 0.5ºC
Withdrawal time : 3hrs with 30min interval  
Volume withdraw : 5 ml
Table no: 14 In Vitro Drug Release study
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Figure No: 34 In-vitro drug release of Promethazine HCl from formulations F1, F2&F3.
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Figure No: 35 In-vitro drug release of Promethazine HCl from formulation F4, F5&F6.
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Figure No: 36 In-vitro drug release of Promethazine HCl from formulation F7 & F8.
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Figure No: 37 In-vitro drug release of Promethazine HCl from formulation F9 & F10.
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Figure No: 38 In-vitro drug release of Promethazine HCl from formulation   F11, F12 &
F13.
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From the in-vitro release study reports, formulations F1 and F4 showed complete drug
release within 90 mins, for F2 and F5 within 120 mins, for F3, F7 and F8 within 150 mins
and for F6, F9, F10, F11, F12 and F13 within 180 mins (Table no 14). Drug release within 5
minute was high in F1 (52.09%) and low in F9 (9.02 %). 
Drug release was found to be decreasing with increasing polymer content. Also drug
release decreased with increasing proportion of glycerine due to increase in thickness. But
formulations with different plasticizers have similar drug release and no effect in drug release
with different plasticizer type. 
The formulation F6 i.e, with HPMC K4M 2.5% and glycerine 50% to the polymer
content have 12.98% release within 5min and release completed within 3hrs. The release
pattern was linear.
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KINETICS STUDIES
To understand the order and mechanism of drug release from buccal patches the data
was subjected to various kinetic equations and plotted according to first order, Higuchi and
Korsemeyer’s equations. The kinetic study results were given in table 15 and figures 39&40.
The kinetic studies with Higuchi’s equation showed linear plots with high regression
co-efficient  value  0.9911  indicated  that  the  mechanism  of  drug  release  was  diffusion
controlled. 
The release profiles after first 5 minutes was found to follow gel-permeation mediated
as the Korsemeyer Peppas plots were linear for all formulations (Fig.40). The release of the
drug was through the swollen matrix of the patch after the initial burst release. 
Table no: 15 Kinetic analysis of release data for Higuchi’s & Korsemeyer Peppas Model
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Sl.No
:
Formulation
Code
R2 values
Higuchi’s  Equation Korsemeyer’s Equation
1 F1 0.8772 0.7582
2 F2 0.9167 0.7825
3 F3 0.9925 0.9184
4 F4 0.9525 0.9019
5 F5 0.9301 0.8042
6 F6 0.9911 0.9275
7 F7 0.9876 08919
8 F8 0.9631 0.8396
9 F9 0.9844 0.9477
10 F10 0.8973 0.8564
11 F11 0.9170 0.8439
12 F12 0.9523 0.9435
13 F13 0.9652 0.9125
RESULTS AND DISCUSSION
Figure no: 39 Higuchi model plot for F6
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Figure no: 40 Korsemeyer’s plot for F6
1 10 100 1000
1
10
100
1000
ULTRA COLLEGE OF PHARMACY, MADURAI 83
RESULTS AND DISCUSSION
EX-VIVO PERMEATION STUDIES
Ex vivo  drug permeation through fresh Goat  buccal  mucosa using Diffusion cell  and the
results were given in table no 16 and figures 41-45.
Permeation study parameters
Donor compartment       : Phosphate buffer pH6.8
Receptor compartment   : Phosphate buffer pH7.4
Apparatus                       : Diffusion cell
Withdrawal time             : 3 hrs with 30 min interval
Volume withdrawn         : 1mL
    
Table No: 16 Ex-vivo Permeation studies
Tim
e
(mi
n)
Cumulative Percent Drug Absorbed
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13
0 0 0 0 0 0 0 0 0 0 0 0 0 0
5 46.15 32.11 15.87
30.9
7
28.6
5
12.0
1
12.9
1 18.57 8.49
14.7
7 31.63
22.5
1
25.4
2
15 54.88 44.68 36.47
39.4
1
42.5
2
30.1
1
36.5
6 45.82
26.7
7
35.8
5 45.41
30.7
4
37.1
8
30 68.32 67.25 44.32
47.0
1
65.1
5
40.5
2
50.8
5 56.38
37.1
5
56.8
1 50.18
37.2
4
48.2
1
60 90.44 80.34 56.44
65.7
8
74.6
2
56.2
1
64.6
7 70.68
53.3
1
63.3
6 64.68
45.0
8
66.1
1
90 98.31 84.58 78.91
99.1
6
81.2
2
64.8
9
75.0
1 92.85
57.8
5
72.9
5 74.01
52.4
3
70.5
2
120 98.49 90.75 97.87
73.6
8
88.6
7 94.54
75.1
1
84.0
5 76.39
70.2
8
85.9
6
150 98.67 89.14
98.7
9
100.6
5
88.5
2
90.6
8 92.78
86.1
4
93.3
8
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Figure No: 41 Ex-vivo drug permeation of Promethazine HCl from formulation F1, F2
& F3.
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Figure No: 42 Ex-vivo drug permeation of Promethazine HCl from formulation F4, F5
& F6.
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Figure No: 43 Ex-vivo drug permeation of Promethazine HCl from formulation F7&F8.
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Figure No: 44 Ex-vivo drug permeation of Promethazine HCl from formulation F9 &
F10.
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Figure No: 45 Ex-vivo drug permeation of Promethazine HCl from formulation F11,
F12&F13.
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The results indicated that Promethazine hydrochloride can permeate easily across the
goat mucosal membrane. This was due to high aqueous and lipid solubility of Promethazine
hydrochloride.  The  cumulative%  Promethazine  hydrochloride  penetrated  through  the
membrane was indicated that the penetration of drug through the Goat cheek membrane was
rapid. The comparison profiles of the different patches showed that permeability behavior
was  same  for  all  the  patches. This  result  reveals  that  Promethazine  hydrochloride  could
possibly permeate through the human buccal membrane.
Correlation of In vitro drug release and ex vivo drug permeation
 A plot between Cumulative % drug release from F6 on X-axis and Cumulative % drug
permeation from F6 on Y-axis obtained was a straight line with R2 value of 0.9994 (Figure
46).   This  shows  in  vitro dissolution  performed  correlates  well  (100%)  with  ex  vivo
permeation  study.  It  further  indicates  the  in  vitro dissolution  study itself  is  sufficient  to
evaluate the permeability of the drug from patches in lieu of ex vivo permeation study.
Figure no: 46 Correlation of In vitro drug release and Ex vivo drug permeation for F6.
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IN-VIVO COMPATIBILITY STUDY
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From  the In-vivo compatibility  study  of  the  buccal  patches  in  human  healthy
volunteers no irritations, no discomfort, no heaviness, no local anaesthetic actions and good
mouth  feel  was  observed.  This  further  confirms  successful  formulation  of  Promethazine
hydrochloride in the form of buccal patch. The tested patches were not detached from the oral
mucosa  over  the  study  period,  which  indicated  that  the  bioadhesion  values  of  the
formulations were satisfactory to retain the patch on the buccal mucosa.
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Motion sickness is a condition in which there exists a disagreement between visually
perceived  movement  and  the  vestibular  system's  sense  of  movement.  Promethazine
hydrochloride is the most suitable drug because of its anti-cholinergic effect and reduces the
nausea experienced during motion sickness.
Because of the low systemic bioavailability and requirement of rapid onset of action
for patients with nausea and motion sickness, buccal mucoadhesive administration dosage
form is effective and safe, and unpleasant taste and local anaesthetic effect on tongue can be
avoided. This  dosage  form  is convenient  for patients  those  who  want  any-time  dosage
especially when travelling.
In the present work successful attempt was made to formulate buccal patches using 10
mg drug loaded in HPMC K4M and HPMC15cps with different plasticizers glycerine, PEG
400 and Propylene glycol in different compositions. 
The objectives for the proposed work are given in chapter III.  Extensive literature
survey was done before the experimental works for collection of theoretical and technical
data. The review of literature is presented in chapter II. The materials and equipments used
throughout the work are listed in chapter IV followed by Drug profile and excipient profiles.
Methodology for the preparation and characteristic evaluations are included in chapter
IV. Drug- excipient compatability was assessed by FTIR spectroscopy. The physicochemical
characteristics such as weight, thickness, folding endurance, surface pH, drug content and
swelling  index  were  evaluated  for  all  formulations.  Tensile  strength  and  mucoadhesion
studies were carried out with TA.XT plus texture analyser. In vitro drug release studies were
carried out in Dissolution apparatus Type VI (cylinder Apparatus). The data was subjected to
various  kinetic  analyses  and  plotted  according  to  first  order,  Higuchi  and  Korsemeyer’s
equations to understand the order and mechanism of drug release.   Ex-vivo diffusion study
through goat buccal mucosa was carried out in Diffusion cell for all the formulations. In-vitro
release ex-vivo correlation study was done.  In-vivo compatibility study of the buccal patch
conducted in 10 healthy human volunteers.
The results obtained are presented in chapter V, in the form of graphs and figures and
are explained and discussed in detail
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The following conclusions were drawn from the present investigation:-
 Buccal mucoadhesive patches containing Promethazine hydrochloride was prepared with
HPMC 15cps and HPMC K4M in different concentrations with different proportions of
glycerine and also with PEG 400 and Propylene glycol.
  The IR spectral data indicates that there was no interaction between drug and the utilized
polymers.
 Each  formulation  was  uniform  in  their  weight  (54.09±0.6-311.12±0.6  mg),  thickness
(77.67±0.33-424.33±2µm) and almost uniform in their drug content with low SD value
and all the patches exhibited folding endurance above 500 proving the flexible nature of
the patch. 
 The surface pH values were found to be between 5.5 and 6.0 for  all  the formulations
which indicate that all the formulations were compatible with the buccal surface.
 Swelling index of the patches was increasing with polymer concentration. Also it increases
with increasing content of glycerine. There is no marked change in swelling nature for
patches with 50% of PEG 400 and Propylene glycol when compared with glycerine.
 Tensile strength and extensibility of the patches with HPMC K4M is higher compared to
patches with HPMC 15cps. Extensibility of the patches increased with increase in polymer
concentration.  The flexibility and  tensile  strength increases  with increasing amount  of
plasticizer  (Glycerine).  There  is  no significant  effect  with  different  plasticizer  type on
extensibility and tensile strength of the patches. 
 The adhesive force of the patches was found to be varying with thickness and swelling
nature  of  the  patches.  Patches  with  PEG  400  and  Propylene  glycol  have  poor
mucoadhesion.  Patches  with  optimum  thickness  and  swelling  nature  showed  good
adhesion (F6). The plasticizer suitable with respect to good mucoadhesion is glycerine.
 Drug release found to be decreasing with increasing proportions of polymer. Also drug
release decreased with increasing proportion of glycerine. But formulations with different
plasticizers have similar drug release and no effect in drug release with different plasticizer
type. 
 The formulation F6 i.e, with HPMC K4M 2.5% and glycerine 50% to the polymer content
have 12.98% release within 5min and release completed within 3hrs. The release pattern is
linear.
 The kinetic studies with Higuchi’s equation showed linear plots indicated (R2=0.9911) that
the mechanism of drug release was diffusion controlled. The release profiles after first 5
minutes was found to follow gel-permeation mediated as the  Korsemeyer Peppas plots
were linear for all formulations. The release of the drug was through the swollen matrix of
the patch after the initial burst release.
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 The permeation across goat mucosal membrane indicated that penetration of Promethazine
hydrochloride was rapid due to high aqueous and lipid solubility.  This result reveals that
Promethazine  hydrochloride  could  possibly  permeate  through  the  human  buccal
membrane.
 In-vitro and Ex-vivo correlation was carried out for formulation F6 and the correlation co-
efficient was found to be 0.9994.
  Results from In-vivo compatibility study exhibited good acceptance of the patches.
 Among the various formulations F6 exhibited optimum thickness, swelling, pH, tensile
strength,  good  bioadhesive  strength,  and  the  drug  release  as  compared  to  other
formulations. Hence the formulation F6 is selected as optimized formulation.
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